Removal of CD41+ and / or CD61+ platelet derived extracellular vesicles (PEVS)

An extracorporeal lectin-based device depletes CD41+ and/or CD61+ PEVs, enhancing treatment efficacy for diseases like Multiple Sclerosis and cancer by up to 80%, addressing the pathogenic role of these vesicles in existing therapies.

WO2026236212A1PCT designated stage Publication Date: 2026-11-12AETHLON MEDICAL INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026690
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing therapies are ineffective in addressing the pathogenic role of CD41+ and/or CD61+ platelet-derived extracellular vesicles (PEVs) in various diseases, including Multiple Sclerosis, Rheumatoid arthritis, Systemic lupus erythematosus, cardiovascular disease, cancer, and thrombosis, leading to suboptimal treatment outcomes.

Method used

Employing an extracorporeal device containing a lectin, such as Galanthus nivalis agglutinin, to bind and deplete CD41+ and/or CD61+ PEVs from blood or plasma samples, followed by reintroduction into the subject, thereby reducing their levels and enhancing the efficacy of conventional therapies.

Benefits of technology

The method effectively reduces CD41+ and/or CD61+ PEVs by up to 80% or more, improving the bioavailability and efficacy of treatments for associated diseases, while minimizing off-target effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026690_12112026_PF_FP_ABST
    Figure US2026026690_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Described herein are methods and devices that deplete or reduce CD41+ and / or CD61+ Platelet Derived Extracellular Vesicles (PEVs), or fragments thereof, which improve the efficacy of therapies used for the treatment of various diseases, such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), vasculitis, Systemic Sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, a hemorrhagic disorder such as disseminated intravascular coagulation (DIC), thrombosis, a blood cell disorder, or any combination thereof. In particular, methods and devices employing extracorporeal devices that deplete CD41+ and / or CD61+ PEVs, or fragments thereof, present in a subject, are provided.
Need to check novelty before this filing date? Find Prior Art

Description

AETH.050WO PATENTREMOVAL OF CD41+ AND / OR CD61+ PLATELET DERIVED EXTRACELLULAR VESICLES (PEVS)FIELD

[0001] Methods and devices that deplete or reduce CD41+ and / or CD61+ Platelet Derived Extracellular Vesicles (PEVs), or fragments thereof, are provided. The methods and devices described herein improve the efficacy of therapies used for the treatment of various diseases, such as Multiple Sclerosis (MS), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, a hemorrhagic disorder, such as disseminated intravascular coagulation (DIC), thrombosis, a blood cell disorder, or any combination thereof. In particular, methods and devices employing extracorporeal devices that deplete CD41+ and / or CD61+ PEVs, or fragments thereof, present in a subject, are provided.BACKGROUND

[0002] Emerging evidence suggests that platelet-derived extracellular vesicles (PEVs) play an important role in the pathogenesis of various diseases, including cancer. PEVs are released from activated platelets and carry numerous components, such as proteins, nucleic acids, and lipids. PEVs also carry numerous surface markers, of which CD41 is commonly used to identify PEVs and facilitate platelet aggregation. As CD41+ and / or CD61+ PEVs are implicated in the pathological process of various diseases, depletion of CD41+ and / or CD61+ PEVs offers a promising therapeutic approach for mitigating the progression of various diseases.SUMMARY

[0003] Aspects of the present disclosure relate to the phenomenon that Platelet- derived EVs, CD41+ve, and CD61+ve extracellular vesicles (platelet microparticles (PMPs)) have been implicated in various diseases.

[0004] A lectin, comprised in an extracorporeal device, suitable for use in a method of reducing an amount of CD41 + and / or CD61 + Platelet Derived Extracellular Vesicles (PEVs) in a subject in need thereof or a sample from a subject, the method comprising: a) contacting a sample from said subject, which contains CD41+ and / or CD61+ Platelet Derived Extracellular Vesicles (PEVs), such as blood or plasma, with a support comprising a lectin, such as a membrane or bead, preferably comprised in an extracorporeal device, for a time sufficient to allow the CD41+ and / or CD61+ PEVs to bind to said support; and b) optionally, reintroducing the sample obtained after (a) into said subject, wherein the sample obtained after (a) has a reduced amount of the CD41+ and / or CD61+ PEVs, as compared to the sample of said subject prior to (a); c) optionally measuring the amount of CD41+ and / or CD61+ PEVs in the sample from said subject prior to (a), after (a), during (b), or after (b), or any combination thereof, or measuring or analyzing the amount of CD41+ and / or CD61+ PEVs present on the support after (a); or d) optionally selecting or identifying the subject as one in need of removal of CD41+ and / or CD61+ PEVs. In some embodiments, the PEVs removed comprise both CD41+ and CD61+.

[0005] In some embodiments, the subj ect has Multiple Sclerosis (MS), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, a hemorrhagic disorder, such as disseminated intravascular coagulation (DIC), thrombosis, or any combination thereof

[0006] In some embodiments, the cardiovascular disease comprises hypertension, heart failure, Acute Coronary Syndrome (ACS), or Acute Myocardial Infarction (AMI).

[0007] In some embodiments, the thrombosis comprises deep vein thrombosis, pulmonary embolism, stroke, or Myocardial infarction (MI).

[0008] In some embodiments, the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than 80 events / pl, or the amount of CD41+ and / or CD61+ PEVs in the sample after (a) is less than or equal to 80 events / pl, preferably greater than or equal to a pl atelet / ab solute lymphocyte ratio (PLR) of 160.

[0009] In some embodiments, the subject can be selected or identified as one in need of removal of CD41+ and / or CD61 + PEVs when the amount of C D41 + and / or CD61+ PEVs in the sample prior to (a) is greater than or equal to 80 events / pl, preferably greater than or equal to a platelet / absolute lymphocyte ratio (PLR) of 160.?

[0010] In some embodiments, the lectin can be suitable for use in reducing off- targeting of a CD41 -directed therapy and / or a CD61 -directed therapy in the subject.

[0011] In an aspect, a method for reducing an amount of CD41+ and / or CD61+ Platelet Derived Extracellular Vesicles (PEVs) in a subject in need thereof or a sample from a subject is provided. In some embodiments, the method comprises: a) contacting a sample from said subject, which contains CD41+ and / or CD61+ Platelet Derived Extracellular Vesicles (PEVs), such as blood or plasma, with a support comprising a lectin, such as a membrane or bead, preferably comprised in an extracorporeal device, for a time sufficient to allow the CD41+ and / or CD61+ PEVs to bind to said support; and b) optionally, reintroducing the sample obtained after (a) into said subject, wherein the sample obtained after (a) has a reduced amount of the CD41+ and / or CD61+ PEVs, as compared to the sample of said subject prior to (a); c) optionally measuring the amount of CD41+ and / or CD61 + PEVs in the sample from said subject prior to (a), after (a), during (b), or after (b), or any combination thereof, or measuring or analyzing the amount of CD41+ and / or CD61+ PEVs present on the support after (a); or d) optionally selecting or identifying the subject as one in need of removal of CD41+ and / or CD61+ PEVs. In some embodiments, the PEVs removed comprise both CD41+ and CD61+.

[0012] In some embodiments, the subject has Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SEE), vasculitis, systemic sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, a hemorrhagic disorder such as disseminated intravascular coagulation (DIC), thrombosis, or any combination thereof.

[0013] In some embodiments, the cardiovascular disease comprises hypertension, heart failure, Acute Coronary Syndrome (ACS), or Acute Myocardial Infarction (AMI).

[0014] In some embodiments, the thrombosis comprises deep vein thrombosis, pulmonary embolism, stroke, or Myocardial Infarction (MI).

[0015] In some embodiments, the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than 1×108PEV s per mL and / or after (a) is less than 1×108PEVs per mL.

[0016] In some embodiments, the contacting reduces the amount of platelet-associated miRNAs in the sample by 30% or more.

[0017] In some embodiments, the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than 80 events / pl, or the amount of CD41+ and / or CD61+ PEVs in the sample after (a) is less than or equal to 80 events / pl, preferably greater than or equal to a platelet / absolute lymphocyte ratio (PLR) of 160. In some embodiments, the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs when the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than or equal to 80 events / pl, preferably greater than or equal to a platelet / absolute lymphocyte ratio (PLR) of 160.

[0018] In an aspect, a method for treating, inhibiting, or ameliorating multiple sclerosis (MS), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis (SS), cardiovascular diseases, atherosclerosis, stroke, cancer, sepsis, Alzheimer’s disease, a hemorrhagic disorder such as disseminated intravascular coagulation (DIC), thrombosis in a subject in need thereof is provided. In some embodiments, the method comprises: a) contacting a sample from said subject, which contains CD41+ and / or CD61+ Platelet Derived Extracellular Vesicles (PEVs), such as blood or plasma, with a support comprising a lectin, such as a membrane or bead, e.g., diatomaceous earth, preferably comprised in an extracorporeal device, for a time sufficient to allow the CD41+ and / or CD61+ PEVs to bind to said support; and b) reintroducing the sample obtained after (a) into said subject, wherein the sample obtained after (a) has a reduced amount of the CD41+ and / or CD61+ PEVs, as compared to the sample of said subject prior to (a); c) optionally measuring the amount of CD41+ and / or CD61+ PEVs in the sample from said subject prior to (a), after (a), during (b) or after (b) or any combination thereof or measuring or analyzing the amount of CD41+ and / or CD61+ PEVs present on the support after (a); optionally selecting or i dentifying a subj ect in need of removal of CD41 + and / or CD61 + PEVs; optionally selecting or identifying said subject for receiving a therapy for multiple sclerosis (MS), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, a hemorrhagic disorder such as disseminated intravascular coagulation (DIC), thrombosis, or a blood cell disorder; or optionally administering to said subject a therapy for Multiple Sclerosis (MS), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, ahemorrhagic disorder such as disseminated intravascular coagulation (DIC), thrombosis, or a blood cell disorder, such as an antibody or binding fragment thereof (e.g., an ScFv or Fab fragment) specific for CD41 or an immune cell having a chimeric antigen receptor specific for CD41 (e.g., a T cell or NK cell). In some embodiments, the PEVs removed comprise both CD41+ and CD61+,

[0019] In some embodiments, the therapy comprises administering a vaccine, a surgery', a drug, a monoclonal antibody, Intravenous immunoglobulin (IVIG), an extracorporeal therapy, an immunotherapy, a chemotherapy, radiation, a blood transfusion, a transplantation, behavioral therapy, or any combination thereof.

[0020] In some embodiments, the therapy comprises administering atezolizumab (TECENTRIQ®), durvalumab (IMFINZI®), avelumab (BAVENCIO®), pembrolizumab (KEYTRUDA®), nivolumab (OPDIVO®), cemiplimab (LIBTAYO®), corticosteroids, muscle relaxants, plasma exchange, immunosuppressants, non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biological agents, physical therapy, occupational therapy, RITUXAN® (rituximab), BENLYSTA® (belimumab), Actemra® (tocilizumab), ORENCIA® (abatacept), anticoagulants, antiplatelet agents, thrombolytics, steroids, antibiotics, Aricept® (Donepezil), Exelon® (Rivastigmine), Razadyne® (Galantamine), ADUHELM® (Aducanumab), LEQEMBI® (Lecanemab), or combinations thereof.

[0021] In some embodiments, the immunotherapy comprises administering a vaccine, an inhibitor of one or more of PD-1, CTLA-4, CCR2, or CCR5 or any combination thereof.

[0022] In some embodiments, the cardiovascular disease comprises hypertension, heart failure. Acute Coronary Syndrome (ACS), or Acute Myocardial Infarction (AMI).

[0023] In some embodiments, the thrombosis comprises deep vein thrombosis, pulmonary embolism, stroke and / or Myocardial infarction (MI).

[0024] In some embodiments, the therapy comprises an agent that targets CD4I, such as an immunotherapy, CD41 -targeting nanoparticles, anti-CD4 I aptamers, CD41 -targeting ligands, CD41 -targeting small molecule inhibitors, or any combination thereof.

[0025] In some embodiments, the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than or equal to 80 events / pl, or the amount of CD41+ and / or CD61+PEVs in the sample after (a) is less than or equal to 80 events / pl, preferably greater than or equal to a pl atelet / ab solute lymphocyte ratio (PER) of 160. In some embodiments, the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs when the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than or equal to 80 events / pl, preferably greater than or equal to a platelet / absolute lymphocyte ratio (PLR) of 160.

[0026] In some embodiments, the method is a method for treating or ameliorating rheumatoid arthritis (RA).

[0027] In some embodiments, the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than 1×108PEVs per mL and / or after (a) is less than 1×108PEVs per mL.

[0028] In some embodiments, the contacting reduces the amount of platelet-associated miRNAs in the sample by 30% or more.

[0029] In an aspect, a method for reducing off-targeting of a CD41 -directed therapy in a subj ect in need thereof is provided. In some embodiments, the method comprises: a) contacting a sample from said subject, which contains CD41+ and / or CD61+ Platelet Derived Extracellular Vesicles (PEVs), such as blood or plasma, with a support comprising a lectin, such as a membrane or bead, preferably comprised in an extracorporeal device, for a time sufficient to allow the CD41+ and / or CD61+ PEVs to bind to said support; and b) reintroducing the sample obtained after (a) into said subject, wherein the sample obtained after (a) has a reduced amount of the CD41+ and / or CD61+ PEVs, as compared to the sample of said subject prior to (a); c) optionally measuring the amount of CD41+ PEVs in the sample from said subject prior to (a), after (a), during (b), or after (b), or any combination thereof, or measuring or analyzing the amount of CD41 + and / or CD61 + PEVs present on the support after (a); (a) optionally selecting or identifying a subject in need of removal of CD41+ and / or CD61+ PEVs; (b) optionally selecting or identifying said subject for receiving a therapy for multiple sclerosis (MS), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, a hemorrhagic disorder such as disseminated intravascular coagulation (DIC), thrombosis; or (c) optionally administering to said subject a therapy for Multiple Sclerosis (MS), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer,sepsis, Alzheimer's disease, a hemorrhagic disorder such as disseminated intravascular coagulation (DIC), thrombosis, such as an antibody or binding fragment thereof (e.g., an ScFv or Fab fragment) specific for CD41 or an immune cell having a chimeric antigen receptor specific for CD41 (e.g., a T cell or NK cell). In some embodiments, the PEVs removed comprise both CD41+ and CD61+,

[0030] In some embodiments, the cardiovascular disease comprises hypertension, heart failure, Acute Coronary Syndrome (ACS), or Acute Myocardial Infarction (AMI).

[0031] In some embodiments, the thrombosis comprises deep vein thrombosis, pulmonary embolism, stroke, and / or Myocardial infarction (MI ).

[0032] In some embodiments, the therapy comprises an agent that targets CD41, such as an immunotherapy, CD41 -targeting nanoparticles, anti-CD41 aptamers, CD41 -targeting ligands, CD41 -targeting small molecule inhibitors, or any combination thereof.

[0033] In some embodiments, the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than or equal to 80 events / pl, or the amount of CD41 + and / or CD61+ PEV s in the sample after (a) is less than or equal to 80 events / pl. In some embodiments, the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs when the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than or equal to 80 events / pl.

[0034] In some embodiments, the method further comprises repeating steps (a) and / or (b).

[0035] In some embodiments, the lectin is selected from the group consisting of Galanthus nivalis lectin (GNA), Narcissus pseudonarcissus lectin (NPA), Allium sativum lectin (ASA), Lens culinaris lectin (LCH), Sambucus nigra lectin (SNA), Maackia amurensis lectin (MAL), and concanavalin A. In some embodiments, the lectin is Galanthus nivalis agglutinin (GNA). In some embodiments, the extracorporeal device comprises a hollow fiber cartridge comprising the lectin and wherein the blood or plasma flows through hollow fibers of the hollow fiber cartridge. In some embodiments, the hollow fibers of the hollow fiber cartridge comprise a pore size that excludes cellular components of the blood or plasma from contacting the lectin. In some embodiments, the pore size is 200-500 nm. In some embodiments, the lectin is immobilized or adsorbed onto a solid support, and the hollow fiber cartridge comprises the lectin immobilized or adsorbed on the solid support. In some embodiments, the solid support comprises diatomaceousearth. In some embodiments, the lectin is immobilized on a support that comprises a material selected from the group consisting of Sepharose, agarose, latex, glass, thermoplastic polymers, polystyrene, polyethylene beads, polyvinyl, diatomaceous earth, nitrocellulose, and silicon.

[0036] In some embodiments, the sample obtained after (a) has a reduced amount of the CD41+ PEVs. In some embodiments, the sample obtained after (a) has a reduced amount of the CD61+ PEVs. In some embodiments, the sample obtained after (a) has a reduced amount of both the CD41+ PEVs and the CD61+ PEVs. In some embodiments, the sample obtained after (a) has a reduced amount of PEVs that comprise both CD41+ and CD61+.BRIEF DESCRIPTION OF THE DRAWINGS

[0037] In addition to the features described above, additional features and variations will be readily apparent from the following descriptions of the drawings and exemplary embodiments. It is to be understood that these drawings depict typical embodiments and are not intended to be limiting in scope.

[0038] FIG. I is a schematic illustration of a longitudinal cross section of an affinity cartridge.

[0039] FIG. 2 is a schematic illustration of a horizontal cross section at plane 2 in FIG. 1.

[0040] FIG. 3 is an illustration of a channel from FIG. 2. A hollow fiber membrane structure 40 is composed of a tubular section comprising a relatively tight ultrafiltration membrane 42 and relatively porous exterior portion 44 in which may be immobilized affinity molecules 46, such as lectins.

[0041] FIG. 4 illustrates the measurement of CD41+ PEVs in plasma samples following contact with a Hemopurifier®.

[0042] FIG. 5A and 5B illustrate the measurement of microvesicles or microparticles and platelet-derived microvesicles in healthy plasma samples following contact with a Hemopurifier®. The data represent the average of two technical replicates and their respective standard deviation. The limit of detection was 5.78×104particles / mL of plasma.

[0043] FIG. 6 A illustrates depletion of CD41+ extracellular vesicles (EVs) duringan example hemopurifier treatment of rheumatoid arthritis plasma.

[0044] FIG. 6B illustrates reduction of platelet-associated miRNAs in rheumatoid arthritis plasma during hemopurifier treatment.

[0045] FIG. 7 illustrates reduction of CD61+ PEVs in healthy plasma samples after hemopurifier treatment.DETAILED DESCRIPTION

[0046] Disclosed herein are methods and devices for depleting or reducing CD41+ and / or CD61+ Platelet Derived Extracellular Vesicles (PEVs) or fragments thereof in a subject. Aspects described herein stem from the discovery that CD41+ and / or CD61+ PEVs are implicated in a variety of diseases, including, but not limited to, Multiple Sclerosis (MS), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, hemorrhagic disorders such as disseminated intravascular coagulation (DIC), thrombosis, a blood cell disorder, or any combination thereof. Accordingly, provided herein are systems and methods to deplete CD41+ and / or CD61+ PEVs from a subject in need thereof, for example, to improve the bioavailability and efficacy of conventional therapies for CD41+ and / or CD61+ associated diseases. In some embodiments, the PEVs removed comprise both CD41+ and CD61+. In particular, described herein are systems and methods comprising an extracorporeal cartridge, configured for use with conventional blood filtration systems, comprising an affinity matrix, which adsorbs CD41+ and / or CD61+ PEVs and improves the efficacy of conventional therapies for CD41+ and / or CD61+ associated diseases. Some embodiments relate to systems and methods of selecting, identifying, or stratifying the subject as one in need of removal of CD41+ and / or CD61+ PEVs. In some embodiments, systems and methods for reducing off-targeting of a CD41 -directed therapy in a subject in need thereof are provided.Definitions

[0047] Unless defined otherwise, technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art. All patents, applications, published applications, and other publications referenced herein are expresslyincorporated by reference in their entireties unless stated otherwise. In the event that there are a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.

[0048] The practice of the present disclosure will employ, unless indicated specifically to the contrary, conventional methods of molecular biology and recombinant DNA techniques within the skill of the art, many of which are described below for the purpose of illustration.

[0049] The terms ‘"individual”, “subject”, or “patient” as used herein, mean a human or a non-human mammal, e.g., a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate, or a bird, e.g., a chicken, as well as any other vertebrate or invertebrate. The “individual”, “subject”, or “patient” may mean a human or a non-human mammal that is alive. The “individual”, “subject”, or “patient” may mean a human or a non-human mammal that is deceased.

[0050] The term “mammal” is used in its usual biological sense. Thus, it specifically includes, but is not limited to, primates, including simians (chimpanzees, apes, monkeys) and humans, cattle, horses, sheep, goats, swine, rabbits, dogs, cats, rodents, rats, mice, guinea pigs, or the like.

[0051] The terms “function” and “functional” as used herein refer to a biological, enzymatic, or therapeutic function.

[0052] The term “isolated” as used herein refers to material that is substantially or essentially free from components that normally accompany it in its native state. For example, an “isolated cell,” as used herein, includes a cell that has been purified from the milieu or organisms in its naturally occurring state, a cell that has been removed from a subject or from a culture; for example, it is not significantly associated with in vivo or in vitro substances.

[0053] The terms “treat”, “treating”, “treatment”, “therapeutic”, or “therapy” as used herein have their ordinary meaning as understood in light of the specification, and do not necessarily mean total cure or abolition of the disease or condition. The term “treating” or “treatment” as used herein (and as well understood in the art) also means an approach for obtaining beneficial or desired results in a subject's condition, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or moresymptoms or conditions, diminishment of the extent of a disease, stabilizing (i.e., not worsening) the state of disease, prevention of a disease's transmission or spread, delaying or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission, whether partial or total and whether detectable or undetectable. “Treating'’ and “treatment” as used herein also include prophylactic treatment. Treatment methods comprise administering to a subject a therapeutically effective amount of an active agent or use of a therapeutic device. The administering step may consist of a single administration or may comprise a series of administrations. The compositions are administered or applied to the subject in an amount, for a duration, or for a number of repetitions sufficient to treat the patient. The length of the treatment period depends on a variety of factors, such as the severity' of the condition, the age and genetic profile of the patient. It will also be appreciated that the treatment or prophylaxis may be modified over the course of a particular treatment or prophylaxis regime. In some instances, chronic administration or application may be required. The term “prophylactic treatment” refers to treating a subject who does not yet exhibit symptoms of a disease or condition, but who is susceptible to, or otherwise at risk of, a particular disease or condition, whereby the treatment reduces the likelihood that the patient will develop the disease or condition. The term “therapeutic treatment” refers to administering treatment to a subject already suffering from or developing a disease or condition.

[0054] The term “inhibit” as used herein has its ordinary meaning as understood in light of the specification, and may refer to, e.g., the reduction of a viral infection or sequela thereof or tissue rejection or the presence of extracellular vesicles or cytokines that mediate an inflammatory response. The reduction can be by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, or an amount that is within a range defined by any two of the aforementioned values. As used herein, the term “delay” has its ordinary meaning as understood in light of the specification, and refers to a slowing, postponement, or deferment of an event, such as a viral infection, or a symptom or sequela thereof, or an inflammatory event to a time which is later than would otherwise be expected. The delay can be a delay of 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or an amount within a range defined by any two of the aforementioned values. The terms “inhibit” and “delay” may not necessarily indicate a 100% inhibition or delay. A partial inhibition or delay may be realized.

[0055] The terms “nucleic acid” or “nucleic acid molecule” as used herein refer to polynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), or fragments generated by any of ligation, scission, endonuclease action, and exonuclease action. Nucleic acid molecules can be composed of monomers that are naturally-occurring nucleotides (such as DNA and RNA), or analogs of naturally-occurring nucleotides (e.g., enantiomeric forms of naturally-occurring nucleotides), or a combination of both. A nucleic acid or nucleic acid molecule can comprise one or more sequences encoding different peptides, polypeptides, or proteins. These one or more sequences can be joined in the same nucleic acid or nucleic acid molecule adjacently, or with extra nucleic acids in between, e.g., linkers, repeats, or restriction enzyme sites, or any other sequence that is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, or 300 bases long, or any length in a range defined by any two of the aforementioned lengths.

[0056] The terms “peptide”, “polypeptide”, and “protein” as used herein refer to macromolecules comprised of amino acids linked by peptide bonds. The numerous functions of peptides, polypeptides, and proteins are known in the art, and include but are not limited to enzymes, structure, transport, defense, hormones, or signaling. Peptides, polypeptides, and proteins are often, but not always, produced biologically by a ribosomal complex using a nucleic acid template, although chemical syntheses are also available. By manipulating the nucleic acid template, peptide, polypeptide, and protein mutations such as substitutions, deletions, truncations, additions, duplications, or fusions of more than one peptide, polypeptide, or protein can be performed. These fusions of more than one peptide, polypeptide, or protein can be joined in the same molecule adjacently, or with extra amino acids in between, e.g., linkers, repeats, epitopes, or tags, or any other sequence that is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, or 300 amino acids long, or any length in a range defined by any two of the aforementioned lengths.

[0057] As used herein, a “lectin” is a protein that binds selectively to polysaccharides and glycoproteins. Although many are insufficiently specific to be useful, certain lectins are highly selective for enveloped viruses. Among lectins which have this property are those derived from Galanthus nivalis in the form of Galanthus nivalis agglutinin (“GNA”),Narcissus pseudonarcissus in the form of Narcissus pseudonarcissus agglutinin (“NPA”), and a lectin derived from blue-green algae Nostoc ellipsosporum called “cyanovirin”, GN A is non-toxic and sufficiently safe, and it has been incorporated into genetically engineered rice and potatoes (Bell et al.. Transgenic Res 10(1): 35-42, 2001; Rao et al., Plant J 15(4): 469-477, 1998). These lectins bind to glycoproteins having a high mannose content such as found in HIV surface proteins (Chervenak et al., Biochemistry 34(16): 5685-5695, 1995).

[0058] As used herein, a “mannose glycoprotein” refers to a glycoprotein having mannose-mannose linkages in the form of a-l—G, a- l—*6 mannose-mannose linkages, such as high-mannose, pauci -mannose, or oligomannose glycoproteins. High-mannose glycans typically contain between five and nine mannose residues attached to the chitobiose (GlcNAc2) core; with some of the mannose being alpha 1-3 or alpha 1-6. Pauci -mannose is an N-glycan moiety containing two core GlcN / Xc residues and two or three mannose residues that do not bear oligosaccharide extensions. Oligomannose is a glycan that is an oligomer composed of mannose units.

[0059] As used herein, “ectosomes” are extracellular vesicles assembled at and released from the plasma membrane, whereas exosomes are released on the exocytosis of multi vesicular bodies (MVBs) Despite their considerable differences, the functions of ectosomes may be largely analogous to those of exosomes. In some contexts, the term ectosonie is used interchangeably with extracellular vesicles or other terms known in the field, including, but not limited to, microparticles, microvesicles, or shedding vesicles.

[0060] The term ‘"cancer” as used herein should be understood to encompass any neoplastic disease which is characterized by abnormal and uncontrolled cell division causing malignant growth or tumor. Cancer cells, unlike benign tumor cells, exhibit the properties of invasion and metastasis and are highly anaplastic. Cancer as used herein may refer to either a solid tumor or tumor metastasis. Non-limiting examples of cancer are non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), advanced or metastatic gastric cancer, gastroesophageal junction cancer, esophageal adenocarcinoma, advanced or metastatic esophageal squamous cell carcinoma (ESCC), esophageal junction cancer, unresectable or metastatic melanoma, resected Stage IIB or Stage IIC melanoma, resected Stage III or Stage IV melanoma, unresectable or metastatic urothelial carcinoma, pleural mesothelioma, classical Hodgkin lymphoma (cHL), Headand neck squamous cell carcinoma (HNSCC), urothelial carcinoma, colorectal cancer (MSI-H or dMMR), hepatocellular carcinoma (HCC), esophageal cancer, cervical cancer, endometrial cancer, stomach cancer, triple-negative breast cancer (TNBC) or combinations thereof.

[0061] The term “tumor” is meant to refer to an abnormal group of cells or tissue that grows by a rapid, uncontrolled cellular proliferation and continues to grow after the stimuli that initiated the new growth cease. Tumors show partial or complete lack of structural organization and functional coordination with the normal tissue, and usually form a distinct mass of tissue, which may be either benign or malignant.

[0062] The term “autoimmune disease” as used herein should be understood to encompass any disease where the body’s immune system attacks its own healthy cells. Non¬ limiting examples of autoimmune diseases are Addison’s disease, celiac disease, dermatomyositis, Graves’ disease, Hashimoto’s thyroiditis, inflammatory bowel disease (e.g., Crohn’s disease, ulcerative colitis), multiple sclerosis, myasthenia gravis, pernicious anemia, reactive arthritis, rheumatoid arthritis, Sjogren syndrome, systemic lupus erythematosus, or type I diabetes.

[0063] Platelet-derived microparticles (PMPs) or platelet-derived extracellular vesicles (PEVs) are extracellular vesicles released from activated platelets. PEVs would include exosomes, which are 30-100 nm in size and of endocytic origin, ectosomes, also known as microparticles or microvesicles, 100-1000 nm in size, and apoptotic cell bodies. PMPs refer to platelet microparticles in the 100-1000 nm size range.Biological samples

[0064] Some embodiments provided herein include or utilize or analyze a biological sample, which can be referred to as a “sample.” As used herein, the term “subject” includes an animal, a mammal, and a human or porcine. A sample, which may be obtained from a subject, can include any organ, tissue, or fluid from the subject that may contain extracellular vesicles, platelet-derived extracellular vesicles (PEVs), and platelet microparticles (PMPs), or fragments thereof. Examples of such samples include peripheral blood, sera, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, bronchioalveolar lavage fluid, semen (including prostatic fluid), Cowper's fluid or pre-ejaculatory fluid, female ejaculate, sweat, fecal matter, hair, tears, cyst fluid,pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, or other lavage or perfusion fluids. A biological sample may also include the blastocyl cavity, umbilical cord blood, or maternal circulation, which may be of fetal or maternal origin. In some embodiments, the sample may also include cell culture samples. The biological sample may also be a tissue sample or biopsy. In some embodiments, the sample comprises ascites fluid from a subject. In some embodiments, the sample comprises plasma from a subject. In some embodiments, the biological sample may be obtained from a subject that is alive. In some embodiments, the biological sample may be obtained from a subject that is dead.Extracellular Vesicles, Platelet-Derived Extracellular Vesicles (PE Vs) and platelet microparticle (PMP)

[0065] Aspects of the invention concern the use of lectin affinity (e.g., employing a column having a substrate to which a lectin, such as Galanthus nivalis (GNA), is attached or a column packed with lectin affinity resin (e.g., GNA)) to remove extracellular vesicles, platelet- derived extracellular vesicles (PEVs) and platelet microparticles (PMPs) or fragments thereof. As used herein, extracellular vesicles are used interchangeably with exosomes or microvesicles, or other terms in the art and incorporated herein by reference (collectively “EVs”) PEVs can be classified as platelet-derived exosomes or PMPs, which are also referred to as platelet-derived microvesicles (PMVs). Microvesicles and microparticles are also used interchangeably. Generally, EVs are small vesicles that are released into the extracellular environment from a variety of different cells, for example, cells that originate from, or are derived from, the ectoderm, endoderm, or mesoderm including any such cells that have undergone genetic, environmental, and / or any other variations or alterations. An EV is typically created intracellularly when a segment of the cell membrane spontaneously invaginates and is ultimately exocytosed (see e.g., Keller et al. (2006), Immunol. Lett. 107: 102-8, incorporated by reference herein in its entirety). In some embodiments, the EVs have a diameter of greater than 10 nm, 20 nm, or 30 nm; a di ameter that is 30-1000 nm, 30-800 nm, 30-200 nm, or 30-100 nm. In some embodiments, EVs have a diameter of less than 10,000 nm, 1000 nm, 800 nm, 500 nm, 200 nm, 100 nm, or 50 nm, EVs may also be referred to as niicrovesicles, tausomes, nanovesicles, vesicles, dEVs, bleb, blebby, prostasomes,microparticles, intralumenal vesicles, endosomal-like vesicles, or exocytosed vehicles. EVs can also include any shed membrane-bound particle that is derived from either the plasma membrane or an internal membrane. EVs can also include cell-derived structures bounded by a lipid bilayer membrane arising from both herniated vagination separation and sealing of portions of the plasma membrane or from the export of any intracellular membrane-bounded vesicular structure containing various membrane-associated proteins of tumor origin, including surface-bound molecules derived from the host circulation that bind selectively to the tumor-derived proteins together with molecules contained in the exosome lumen including tumor-derived microRNAs or intracellular proteins. EVs can also include membrane fragments. Generally, EVs carry a broad variety of membrane-associated biologically-active molecules, including cell adhesion molecules necessary for exosome uptake by recipient cells via phagocytosis, endocytosis, fusion with the membrane, or receptor-mediated uptake. In reference to the disclosure herein, EVs or a unit of EVs may refer to the entire amount of EVs present in a subject, or an amount that is less than the entire amount of EVs present in a subject. In some embodiments, greater than or equal to 20%, 30%, 40%, 50%, 60%, 70%, or 80% of extracellular vesicles found in the circulation are derived from platelets (PEVs) or the amount of PEVs in the circulation of a subject in need of a therapy described herein is an amount that is within a range defined by any two of the aforementioned amounts, such as 20%-30%, 30%-40%, 40%-50%, 50%-60%, 60%-70%, or 70%-80%, or greater than 80%. In some embodiments, the PEVs have a diameter greater than 10 nm, 20 nm, or 30 nm; a diameter that is 30- 1000 nm, 30-800 nm, 30-200 nm, or 30-100 nm, In some embodiments, PEVs have a diameter of less than 10,000 nm, 1000 nm, 800 nm, 500 nm, 200 nm, 100 nm, or 50 nm. In some embodiments, the PEVs have a diameter less than 1 mm. In some embodiments, the PEVs have a diameter that is 100-500 nm, 150-300 nm, 200-300 nm, 250-350 nm, 300-450 nm, or 100-400 nm.

[0066] Exosomes are present in the systemic circulation and are distributed throughout the body. Exosomes are found to be present in almost all kinds of body fluids, such as blood, plasma, cerebrospinal fluid, bile, urine, breast milk, and others, and are generated by the endosomal pathway. In normal, healthy individuals, a basal level of exosome release aids in cell- to-cell communication and promotes elimination of cellular debris. However, an increase in exosome quantity is a potent symptom of altered physiological states and progression of disease. Exosomes are a part of a communication system that conveys signals to near or distant target cellsand reprograms their functions. Exosome generation can be triggered by many factors, including extracellular stimuli (e.g., microbial attack) and other stresses. Exosomes are generated by most, if not all, cells. The contents of EV s vary' and can include nucleic acids, proteins, and lipids. They can be transferred from host to recipient cells to alter cellular function. Exosomes are secreted by most cell types, including tumor cells, antigen-presenting cells (APC), hematopoietic cells, reticulocytes, mast cells, platelets, and intestinal epithelial cells, both in vivo and in vitro. Depending on their origin, EVs cany specific protein markers (Eustes et al., Int. J. Mol. Sci. 2022, 23, 7837). Proteins enriched in EVs include tetraspanin family members (CD41, CD9, CD63, CD81, CD82) and endosomal sorting complexes required for transport (Alix and TSG101), as well as members of the GTPase family (Rab27, Rabi 1, Rab35) and heat-shock proteins (Hsp60, Hsp70, and Hsp90)

[0067] Platelet-Derived Extracellular Vesicles (PEVs) or platelet microparticles (PMP) are a specific type of extracellular vesicles released from platelets. As used herein, PEVs are used interchangeably with PMPs, or other terms in the art and incorporated herein by reference, PEV s or PMPs are released when platelets are activated. Activation of platelets that results in the release of PEVs or PMPs or fragments thereof can occur due to various stimuli, such as inflammation or injury', apoptosis, or certain diseases. PEVs or PMPs often contain platelet¬ specific markers, such as CD41, CD42b, CD61, CD61p, CD62p, CD63, CD9, PAC-1 (Activated Platelet Integrin ctllb|33), thrombomodulin, platelet factor 4 (PF4), and fibrinogen receptor (allbp3) (Reininger AJ et al, Blood. 2006; 107:3537-45). CD41 is a glycoprotein that plays a key role in platelet aggregation, and CD41+ and / or CD61+ PEVs have been implicated in various diseases, including autoimmune disorders, cardiovascular diseases, Alzheimer’s disease, and cancer. Platelet-Derived Extracellular Vesicles (PEVs) or platelet microparticles (PMP) can also include membrane fragments.

[0068] Aspects of the invention concern the use of lectin affinity (e.g., employing a column having a substrate, such as diatomaceous earth, to which a lectin, such as GNA, NPA, SNA, and / or MAL, is attached, or a column comprising a lectin affinity resin (e.g., GNA)) to remove CD41+ and / or CD61+ PEVs or platelet microparticles (PMP) or fragments thereof from a subject. In some embodiments, the PEVs removed by the column comprise both CD41+ and CD61+. In some embodiments, the CD41 + and / or CD61+ PEVs or platelet microparticles (PMP)or fragments thereof are from subjects having cancer or subjects believed to be at risk for developing cancer, such as non-small cell lung cancer (NSCEC), renal cell carcinoma (RCC), advanced or metastatic gastric cancer, gastroesophageal junction cancer, esophageal adenocarcinoma, advanced or metastatic esophageal squamous cell carcinoma (ESCC), esophageal junction cancer, unresectable or metastatic melanoma, resected Stage IIB or Stage IIC melanoma, resected Stage III or Stage IV melanoma, unresectable or metastatic urothelial carcinoma, pleural mesothelioma, classical Hodgkin lymphoma (cHL), Head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, colorectal cancer (MSI-H or dMMR), hepatocellular carcinoma (HCC), esophageal cancer, cervical cancer, endometrial cancer, stomach cancer, triple-negative breast cancer (TNBC), or combinations thereof.

[0069] Aspects of the invention concern the use of lectin affinity (e.g., employing a column having a substrate, such as diatomaceous earth, to which a lectin, such as GNA, NPA, SNA, and / or MAL, is attached, or a column comprising a lectin affinity resin (e.g., GNA)) to remove CD41+ and / or CD61+ PEVs or platelet microparticles (PMP) or fragments thereof from a subject. In some embodiments, the CD41+ and / or CD61+ PEVs or platelet microparticles (PMP) or fragments thereof are from subjects having an autoimmune disease or subjects believed to be at risk for developing autoimmune disease. Non-limiting examples of autoimmune disease are multiple sclerosis (MS), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis ( SS), or combinations thereof.

[0070] In some embodiments, the CD41+ and / or CD61+ PEVs or platelet microparticle (PMP) or fragments thereof are from subjects having a cardiovascular disease or subjects believed to be at risk for developing a cardiovascular disease. Non-limiting examples of cardiovascular disease are hypertension, stroke, heart failure, acute coronary syndrome (ACS), acute myocardial infarction (AMI), or combinations thereof.

[0071] In some embodiments, the CD41+ and / or CD61+ PEVs or platelet microparticle (PMP) or fragments thereof are from subjects having sepsis or subjects believed to be at risk for developing sepsis. In some embodiments, the CD41+ and / or CD61+ PEVs or platelet microparticle (PMP) are from subjects having Alzheimer's disease or subjects believed to be at risk for developing Alzheimer's disease.

[0072] Aspects of the present invention include using extracorporeal therapies andmethods for contacting blood and / or plasma from said subject having CD41+ and / or CD61+ PEVs or PMP or fragments thereof with a column having a substrate, such as diatomaceous earth, to which a lectin such as GNA is attached or a column packed with lectin affinity resin (e.g., GNA) for a time suffi cient to bind said CD41+ and / or CD61+ PEVs or PMP or fragments thereof to said diatomaceous earth and / or lectin or a column packed with lectin affinity resin (e.g., GNA) and reintroducing the blood and / or plasma from said subject back into said subject, wherein the blood, plasma that is reintroduced, i.e., after contact with the column, has less CD41+ and / or CD61+ PEV s or PMP or fragments thereof than the blood or plasma from said subject prior to contact with the column. In some embodiments, the PEVs removed comprise both CD41+ and CD61 +. In some embodiments, the subject is selected or identified as one in need of removal of CD41+ and / or CD61 + PEVs or PMP or fragments thereof. Such a selection or identification of a subject in need of removal of CD41+ and / or CD61+ PEVs or PMP or fragments thereof can be made using diagnostic evaluation of a biological sample from a subject for the presence and / or amount of CD41+ and / or CD61+ PEVs or PMP or fragments thereof, which can be accomplished by isolating CD41+ and / or CD61+ PEVs or PMP or fragments thereof from the biological sample and analyzing the presence or amount of CD41+ and / or CD61+ PEVs or PMP or fragments thereof using ELISA or an immune assay, which detects or measures the amount of CD41+ and / or CD61+ PEVs or PMP or fragments thereof. Such anti-CD41 antibodies are well known and commercially available from Proteintech® (Cat No. 24552- LAP, Cat No. 60350-1-Ig, or Cat No. 65173-1-Ig) or Creative Biolabs® (CAT#: MOB-0056MZ) or Absolute Antibody (Product Code: Ab00222-21.0).

[0073] In some embodiments, the concentration of CD41+ and / or CD61+ PEVs or PMP in said subject before undergoing the extracorporeal therapies and methods disclosed herein is greater than 80 events / pL. In some embodiments, the concentration of CD41+ and / or CD61+ PEVs or P P in said subject before undergoing the extracorporeal therapies and methods disclosed herein is about 1000 events / pL. In some embodiments, the concentration of CD41+ and / or CD61+ PEVs or PMP in said subject before undergoing the extracorporeal therapies and methods disclosed herein is about 3000 events / pL. In some embodiments, the concentration of CD41+ and / or CD61+ PEVs or PMP in said subject before undergoing the extracorporeal therapies and methods disclosed herein is about 80, 90, 100, 1,000, 10,000, 100,000, 1,000,000, 10,000,000, 100,000,000, 1,000,000,000 events / pL or any concentration between 80 events / pL and1,000,000,000 events / [.iL. In some embodiments, the concentration of CD41+ and / or CD61+ PEVs or PMP in said subject before undergoing the extracorporeal therapies and methods disclosed herein can be quantified using methods well known in the art, including, but not limited to, flow cytometry, chromatography, electron microscopy, or nanoparticle tracking analysis (NTA). In some embodiments, the pl atelet-to-ab solute lymphocyte ratio (PER) in said subject before undergoing the extracorporeal therapies and methods disclosed herein is greater than 150. In some embodiments, the platelet-to-absolute lymphocyte ratio (PER) in said subject before undergoing the extracorporeal therapies and methods disclosed herein is greater than 160. In some embodiments, the platelet-to-absolute lymphocyte ratio (PLR) in said subject before undergoing the extracorporeal therapies and methods disclosed herein is greater than 150, 160, 170, 180, 190, 200, 250, or 300.

[0074] In some embodiments, the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs or PMP if the concentration of CD41+ and / or CD61+ PEVs or PMP in said subject before undergoing the extracorporeal therapies and methods disclosed herein is greater than 80 events / pL. In some embodiments, the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs or PMP if the concentration of CD41+ and / or CD61+ PEVs or PMP in said subject before undergoing the extracorporeal therapies and methods disclosed herein is greater than 1000 events / pL. In some embodiments, the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs or PMP if the concentration of CD41+ and / or CD61+ PEVs or PMP in said subject before undergoing the extracorporeal therapies and methods disclosed herein is greater than 3000 events / pL. In some embodiments, the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs or PMP if the concentration of CD41+ and / or CD61 + PEVs or PMP in said subject before undergoing the extracorporeal therapies and methods disclosed herein is greater than about 80, 90, 100, 1000, 10000, 100000, 1000000, 10000000, 100000000, 1000000000 events / pL or any concentration between 80 events / pL and 1000000000 events / pL. In some embodiments, the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs or PMP if the platelet-to-absolute lymphocyte ratio (PLR) in said subject before undergoing the extracorporeal therapies and methods disclosed herein is greater than 150. In some embodiments, the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs or PMP if the platelet-to-absolute lymphocyte ratio (PER) in said subject before undergoing theextracorporeal therapies and methods disclosed herein is greater than 160. In some embodiments, the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs or PMP if the platelet-to-absolute lymphocyte ratio (PLR) in said subject before undergoing the extracorporeal therapies and methods disclosed herein is greater than 150, 160, 170, 180, 190, 200, 250, or 300.

[0075] In some embodiments, the concentration of CD41+ and / or CD61+ PEVs or PMP in said subject after undergoing the extracorporeal therapies and methods disclosed herein is lower than 80 events / pL. In some embodiments, the concentration of CD41+ and / or CD61+ PEV s or PMP in said subject after undergoing the extracorporeal therapies and methods disclosed herein is less than, about 1000 events / pL. In some embodiments, the concentration of CD41+ and / or CD61+ PEVs or PMP in said subject after undergoing the extracorporeal therapies and methods disclosed herein is less than about 3000 events / pL. In some embodiments, the concentration of CD41+ and / or CD61+ PEV s or PMP in said subject after undergoing the extracorporeal therapies and methods disclosed herein is less than about, 80, 90, 100, 1000, 10000 events / pL or less than any concentration between 80 events / pL and 10000 events / pL. In some embodiments, the concentration of CD41 + and / or CD61+ PEVs or PMP in said subject after undergoing the extracorporeal therapies and methods disclosed herein can be quantified using methods well known in the art, including, but not limited to flow cytometry, chromatography, electron microscopy or nanoparticle tracking analysis (NTA). In some embodiments, the platelet-to- absolute lymphocyte ratio (PLR) in said subject after undergoing the extracorporeal therapies and methods disclosed herein is lower than 150. In some embodiments, the platelet-to-absolute lymphocyte ratio (PLR) in said subject after undergoing the extracorporeal therapies and methods disclosed herein is greater than 160. In some embodiments, the platelet-to-absolute lymphocyte ratio (PLR) in said subject after undergoing the extracorporeal therapies and methods disclosed herein is lower than 160, In some embodiments, the platelet-to-absolute lymphocyte ratio (PLR) in said subject after undergoing the extracorporeal therapies and methods disclosed herein is lower than 150, 160, 170, 180, 190, 200, 250, or 300.

[0076] In some embodiments, the extracorporeal therapies and methods disclosed herein can be used to remove the CD41+ and / or CD61+ PEVs or PMPs from a subject in need in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours, within a24-hour period, or any amount of time within a range defined by any two of the aforementioned times. In some embodiments, the extracorporeal therapies and methods disclosed herein can be used to remove the CD41+ and / or CD61+ PEVs or PMPs from a subject in need in 2 hours. In some embodiments, the extracorporeal therapies and methods disclosed herein can be used to remove the CD41+ and / or CD61+ PEVs or PMPs from a subject in need in 3 hours. In some embodiments, the extracorporeal therapies and methods disclosed herein can be used to remove the CD41 + and / or CD61+ PEV s or PMPs from a subject in need in 4 hours. In some embodiments, the extracorporeal therapies and methods disclosed herein can be used to remove the CD41+ and / or CD61+ PEVs or PMPs from a subject in need in 5 hours. In some embodiments, the extracorporeal therapies and methods disclosed herein can be used to remove the CD41+ and / or CD61+ PEVs or PMPs from a subject in need in 8 hours. In some embodiments, the extracorporeal therapies and methods disclosed herein can be used to remove the CD41+ and / or CD61+ PEVs or PMPs from a subject in need in 10 hours.Substrates

[0077] Some embodiments herein include a substrate, which may be present or comprised in a vessel. In some embodiments, the substrate or support comprises a surface to which CD41+ and / or CD61+ PEVs or PMP binding material (e.g., such as an antibody, lectin, ionic or non-ionic coating) is bound or immobilized. Substrates can include, but are not limited to, for example, a surface, which may be in a vessel (e.g., a plate or microtiter well), beads, membranes, or fibers. A substrate can comprise appropriately functionalized matrices (e.g., ionic or non-ionic resins, Sepharose, latex, glass, polyethylene beads, polystyrene, polyvinyl, polyacrylamide, nitrocellulose, diatomaceous earth, zeolites, or silicon).Extracorporeal Therapy Methods

[0078] In accordance with the present invention, systems, methods, compositions, and devices for extracorporeal treatment or therapy of subjects as disclosed herein can be integrated (in whole or in part) with the methods described herein to deplete CD41+ and / or CD61+ PEVs or PMP or fragments thereof ex vivo in a physiologically applicable manner. In some embodiments, the PEVs removed comprise both CD41+ and CD61+. Exemplary methods contemplated for use herein include: a) hemofiltration; b) hemodialysis; or c) hemodiafiltration,with a preferred method including apheresis followed by filtration.

[0079] In accordance with various embodiments, extracorporeal removal of CD41+ and / or CD61+ PEVs or PMP or fragments thereof can be performed through selective adhesion of said CD41+ and / or CD61+ PEVs or PMP or fragments thereof to matrices or substrates that are conjugated to agents possessing higher affinity to CD41+ and / or CD61+ PEVs or PMP with a high sugar content, in comparison to CD41+ and / or CD61+ PEV s or PMP of a lower sugar content. In some embodiments, CD41+ and / or CD61 + PEVs or PMP or fragments thereof from subjects with a disease are more mannosylated relative to the CD41+ and / or CD61+ PEVs or PMP or fragments thereof from healthy subjects, thereby making CD41+ and / or CD61+ PEVs or PMP more susceptible to binding by mannose-specific lectins.

[0080] In accordance with yet another embodiment, there are provided methods of extracorporeally removing CD41+ and / or CD61+ PEVs or PMP or fragments thereof from a subject in need thereof, said method comprising passing said subject’s separated blood components through a system capable of or configured for selectively binding and retaining CD41+ and / or CD61+ PEVs or PMP or fragments thereof based on one or more of size, charge, affinity towards lectins, or affinity towards molecules that are known to be present on said microvesicles.

[0081] In accordance with a further embodiment, there are provided methods of extracorporeally removing CD41+ and / or CD61+ PEVs or PMP or fragments thereof from a subject in need thereof, said methods comprising passing said subject’s separated blood components through a system capable of or configured for non- selectively binding and retaining CD41+ and / or CD61+ PEVs or PMP or fragments thereof based on one or more of size, charge, affinity towards lectins, or affinity towards molecules that are known to be present on said CD41+ and / or CD61+ PEVs or PMP.

[0082] In some embodiments, a method for treating, inhibiting, or ameliorating multiple sclerosis (MS), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis (SS), cardiovascular diseases, atherosclerosis, stroke, cancer, sepsis, Alzheimer’s disease, a hemorrhagic disorder such as disseminated intravascular coagulation (DIC), thrombosis, or a blood cell disorder in a subject in need thereof is provided. In some embodiments, the method comprises contacting a sample from said subject, which contains CD41+ and / or CD61+ Platelet Derived Extracellular Vesicles (PEVs), such as blood or plasma, with a supportcomprising a lectin, such as a membrane or bead, preferably comprised in an extracorporeal device, for a time sufficient to allow the CD41 + and / or CD61+ PEVs to bind to said support. In some embodiments, the method comprises reintroducing the sample obtained after contact with the extracorporeal device into said subject, wherein the sample obtained after contact with the extracorporeal device has a reduced amount of the CD41+ and / or CD61+ PEVs, as compared to the sample of said subject prior to contact with the extracorporeal device. In some embodiments, the amount of CD41+ and / or CD61+ PEVs in the sample from said subject prior to, after, or during the extracorporeal treatment is measured. In some embodiments, the amount of CD41+ and / or CD61+ PEVs present on the support after contact with the column has fewer CD41 + and / or CD6I + PEVs or PMP or fragments thereof than the blood or plasma from said subject prior to contact with the column. In some embodiments, the PEVs removed comprise both CD41+ and CD61+. In some embodiments, the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs or PMP or fragments thereof. In some embodiments, the subject is selected or identified for receiving a therapy for multiple sclerosis (MS), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, a hemorrhagic disorder such as disseminated intravascular coagulation (DIC), thrombosis, or a blood cell disorder.

[0083] In some embodiments, the subject is administered a therapy for multiple sclerosis (MS), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, a hemorrhagic disorder such as disseminated intravascular coagulation (DIC), thrombosis, or a blood cell disorder. In some embodiments, the therapy comprises administering a vaccine, a surgery, a drug, a monoclonal antibody, an extracorporeal therapy, an immunotherapy, a chemotherapy, radiation, a blood transfusion, Intravenous immunoglobulin (IVIG), a transplantation, behavioral therapy, or any combination thereof. In some embodiments, the therapy comprises treating the subject with atezolizumab (TECENTRIQ®), durvalumab (IMFINZI®), avelumab (BAVENCIO®), pembrolizumab (KEYTRUDA®), nivolumab (OPDIVO®), cemiplimab (LIBTAYO®), or any combinations thereof. In some embodiments, the therapy comprises treating the subject with corticosteroids, muscle relaxants, plasma exchange, immunosuppressants, Non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biological agents, physical therapy, occupational therapy, or anycombinations thereof. In some embodiments, the therapy comprises treating the subject with RITUXAN® (rituximab), BENLYSTA® (belimumab), Actemra® (tocilizumab), ORENCIA® (abatacept), or any combinations thereof. In some embodiments, the therapy comprises treating the subject with anticoagulants, antiplatelet agents, thrombolytics, steroids, antibiotics, or combinations thereof. In some embodiments, the therapy comprises treating the subject with Aricept® (Donepezil), Exelon® (Rivastigmine), Razadyne® (Galantamine), ADUHELM® (Aducanumab), LEQEMBI® (Lecanemab), or any combinations thereof.

[0084] In some embodiments, methods of increasing the efficacy, bioavailability, or efficiency of a therapy for a subject in need thereof are provided, the methods comprising reducing the amount of CD41+ and / or CD61+ PEVs from the circulatory system of said subject and administering to said subject an effective amount of a drug or treatment for a disease (e.g., anti-PD-1, anti-PD-Ll therapy). In some embodiments, the therapy comprises administering a vaccine, a surgery, a drug, an extracorporeal therapy, an immunotherapy, a chemotherapy, radiation, a blood transfusion, a transplantation, behavioral therapy, or any combination thereof. In some embodiments, the therapy comprises administering to the subject atezolizumab (TECENTRIQ®), durvalumab (IMFINZI®), avelumab (BAVENCIO®), pembrolizumab (KEYTRUDA®), nivolumab (OPDIVO®), cemiplimab (LIBTAYO®), or any combinations thereof. Some embodiments reduce off-targeting of a CD41 directed therapy in a subject. In some embodiments, the present invention reduces sequestration of CD41 directed drugs. In some embodiments, the therapy comprises an agent that targets CD41, such as an immunotherapy (an anti-CD41 antibody or binding fragment thereof), CD41-targeting nanoparticles, anti-CD41 aptamers, CD41-targeting ligands, CD41-targeting small molecule inhibitors, or any combination thereof. Some embodiments reduce off-targeting of a CD61 directed therapy in a subject. In some embodiments, the present invention reduces sequestration of CD61 directed drugs. In some embodiments, the therapy comprises an agent that targets CD61, such as an immunotherapy (an anti-CD61 antibody or binding fragment thereof), CD61-targeting nanoparticles, anti-CD61 aptamers, CD61-targeting ligands, CD61-targeting small molecule inhibitors, or any combination thereof.Exemplary Lectin-based Extracorporeal Devices

[0085] Disclosed herein are extracorporeal devices and methods of use for removing CD41+ and / or CD6I+ PEVs or PMP or fragments thereof in a subject. In some embodiments, the subject has one or more of: cancer, cardiovascular disease, sepsis, Alzheimer’s disease, or an autoimmune disorder. The extracorporeal devices comprise a lectin that binds to various glycoprotein-containing biological components, such as CD41+ and / or CD61+ PEVs, PMP or fragments thereof. When used for hemofiltration, the extracorporeal device with the lectin can filter, for example, CD41+ and / or CD61+ PEVs, PMP or fragments thereof.

[0086] Once identified or selected as a subject that would benefit from a lectin and / or antibody affinity therapy (e.g., Hemopurifier® therapy) utilizing the methods described herein, one can provide a lectin and / or antibody affinity therapy, such as Hemopurifier® therapy, to said identified or selected subjects. Such methods of selection or identification can be made by clinical evaluation or analysis of samples from said subject (e.g., analysis of samples from said subject for the presence of CD41+ and / or CD61+ PEVs, PMP or fragments thereof). In some embodiments, the subject is selected or identified as one that would benefit from a lectin and / or antibody affinity therapy (e.g., Hemopurifier® therapy) utilizing the methods described herein if the concentration of CD41+ and / or CD61+ PEVs or PMP in said subject before undergoing lectin and / or antibody affinity therapy (e.g., Hemopurifier® therapy) disclosed herein is greater than 80 events / jiL. In some embodiments, the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs or PMP if the concentration of CD41+ and / or CD61+ PEVs or PMP in said subject before undergoing lectin and / or antibody affinity therapy (e.g., Hemopurifier® therapy) disclosed herein is greater than 1000 events / pL. In some embodiments, the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs or PMP if the concentration of CD41+ and / or CD61+ PEVs or PMP in said subject before undergoing lectin and / or antibody affinity therapy (e.g., Hemopurifier® therapy) disclosed herein is greater than 3000 events / pL. In some embodiments, the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs or PMP if the concentration of CD41+ and / or CD61+ PEVs or PMP in said subject before undergoing lectin and / or antibody affinity therapy (e.g., Hemopurifier® therapy) disclosed herein is greater than, or greater than about 80, 90, 100, 1000, 10000, 100000, 1000000, 10000000, 100000000, 1000000000 events / pL, or any concentration between 80events / pL and 1000000000 events / pL. In some embodiments, the subject is selected or identified as one in need of removal of CD41 + and / or CD61+ PEVs or PMP if the platelet-to-absolute lymphocyte ratio (PLR) in said subject before undergoing the extracorporeal therapies and methods disclosed herein is greater than 150. In some embodiments, the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs or PMP if the platelet-to-absolute lymphocyte ratio (PLR) in said subject before undergoing the extracorporeal therapies and methods disclosed herein is greater than 160. In some embodiments, the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs or PMP if the platelet-to-absolute lymphocyte ratio (PLR) in said subject before undergoing the extracorporeal therapies and methods disclosed herein is greater than 150, 160, 170, 180, 190, 200, 250, or 300.

[0087] Within the knowledge of one skilled in the art, numerous types of hollow fiber systems are available. Selection of said hollow fiber system is dependent on the desired plasma volume and rate of passage of said plasma volume through the hollow fiber system. Specifically, hollow fiber cartridges may be used having lengths of 250 mm and containing 535 hollow fibers supplied by Amicon®, and having the fiber dimensions: I.D. 180 micron and O.D.360 micron, and the total contact surface area in the cartridge is 750 cm2. In some embodiments, hollow fiber cartridges having fiber lengths of 225 mm can be used. Alternatively, the " Plasmaflux P2" hollow fiber filter cartridge (sold by Fresenius®) or Plasmart 600 cartridges (sold by Medica S.p. A.) may be used. These and other hollow fiber systems are described by Ambrus and Horvath in U. S. Pat. No. 4,714,556, hereby expressly incorporated by reference in its entirety. Hollow fiber cartridges such as described by Tullis in U. S. Patent Application 20040175291 (hereby expressly incorporated by reference herein in its entirety) may also be used. Furthermore, said hollow fiber cartridges and affinity cartridges in general are described in U. S. Pat. Nos. 4,714,556, 4,787,974, and 6,528,057, all of which are hereby expressly incorporated herein by reference in their entireties.

[0088] Regardless of the hollow fiber system used, the concept needed for application of these embodiments is that said hollow fiber filters are required to allow passage of plasma derived from blood cells through the interior of said hollow fiber, and allow diffusion of CD41+ and / or CD61+ PEVs or PMP or fragments thereof to the exterior. In order to allow such diffusion, the pores on the membrane of the hollow fiber need to be of a diameter sufficient toallow particles ranging from the size of 20 nanometers to 500 nanometers in diameter. More specifically, the pores on the membrane of the hollow fiber need to be of a diameter sufficient to allow particles ranging from the size of 50 nanometers to 300 nanometers in diameter. Even more specifically, the pores on the membrane of the hollow fiber need to be of a diameter sufficient to allow particles ranging from the size of 80 nanometers to 200 nanometers in diameter. In some embodiments, the pores on the membrane of the hollow fiber need to be of a diameter sufficient to allow particles ranging from the size of 200 nanometers to 500 nanometers in diameter. During experimentation with different hollow fibers, one skilled in the art would find it useful to utilize particles of similar size ranges as the microvesicles in order to calibrate and quantitate the ability of various pore sizes of hollow filters. One method of performing this is through the utilization of commercially available MACS Beads (Miltenyi Biotech), which have a size of 60 nanometers.

[0089] The substrate or matrix to be used in practicing these embodiments preferably allows sufficient permeation of flow so that non-cellular blood components that enter the space exterior to the hollow fiber are distributed throughout the substrate or matrix material, so that substantial contact is made between the CD41+ and / or CD61+ PEVs or PMP or fragments thereof permeating the hollow fiber filter and the CD41+ and / or CD61+ PEVs or PMP-binding agent that is attached to the substrate or matrix. Suitable substrates or matrices are known to one skilled in the art. Said substrates or matrices include silica gel, dextran, agarose, nylon polymers, polymers of acrylic acid, co-polymers of ethylene and maleic acid anhydride, aminopropylsilica, aminocelite, glass beads, or silicate containing diatomaceous earth or other substrates or matrices known in the art. Examples of such are described in the following patents, each of which is hereby expressly incorporated by reference in its entirety: Lentz U. S. Pat. No. 4,708,713, Motomura U. S. Pat. No. 5,667,684, Takashima et al. U. S. Pat. No. 5,041,079, and Porath and Janson U. S. Pat. No.3,925,152.

[0090] In order to achieve non-specific removal of CD41+ and / or CD61+ PEVs or PMP or fragments thereof, another embodiment involves the use of hollow fiber filters of sufficient size of the pores on the side of the hollow fiber filter for CD41+ and / or CD61+ PEVs or PMP or fragments thereof to exit, while not allowing plasma derived from the blood cells to exit, and passing a continuous solution over said hollow fiber filters in order to clear said CD41+ and / or CD61 + PEVs or PMP or fragments thereof leaking through the sides of the hollow fiber filters. Insuch a situation, it would be critical to re-introduce the plasma components that escaped the hollow fiber filter, such as albumin, back into the CD41+ and / or CD61+ PEVs or PMP or fragments thereof purified blood, before returning the blood to the subject.

[0091] Alternatively, the hollow-fiber cartridge may be sealed as described in Ambrus (U. S. Pat. No. 4,714,556), expressly incorporated by reference in its entirety. In such a system, both diffusion and convection cause plasma (exclusive of blood cells) to pass through the pores in the hollow fibers and into contact with the capture molecules bound to the solid phase matrix. The fluids (e.g., plasma) pass back into the circulation at the distal end of the cartridge through a process known as Starling flow. In this system, there is no significant loss of plasma and therefore no need for blood component replacement.

[0092] In a situation where disease-specific CD41+ and / or CD61+ PEVs or PMP or fragments thereof are meant to be withdrawn without a certain degree of selectivity from the systemic circulation of a subject in need thereof, said agent binding the matrix or substrate may be a lectin. Specific methodologies for use of lectins in removal of viruses are described by Tullis in U. S. Patent Application 20040175291 (hereby expressly incorporated by reference in its entirety), and these methodologies may also be used in part or in whole for practicing the present invention. In various embodiments of the invention, it is desired that said systems maintain the blood at conditions similar to those found in the host, so that upon returning said blood to the host, no adverse reactions occur. In other words, it is within the scope of the invention to use technologies that are known to one skilled in the art to maintain blood at physiological ion concentrations, osmolality, pH, hematocrit, temperature, and flow in order to avoid harm being caused to the subject subsequent to reinfusion of blood treated as disclosed herein. Said technologies are well known to one skilled in the art.

[0093] In another embodiment, a system for extracorporeal clearance of CD41+ and / or CD61+ PEVs or PMP or fragments thereof, either by selectively removing CD41+ and / or CD61+ PEVs or PMP or fragments thereof, or non-selectively removing CD41+ and / or CD61 + PEVs or PMP or fragments thereof that are found in healthy subjects as well as subjects with a disease, is provided. In some embodiments, the PEVs removed comprise both CD41+ and CD61+. The invention comprises several interacting components whose primary purpose is the formation of a functional circuit capable of depleting CD41+ and / or CD61+ PEVs or PMP or fragmentsthereof in order to de-repress, or in some cases augment, the immune response of a patient with a disease. More specifically, the separation of blood from a subject in need thereof (e.g., a cancer patient) into plasma and cellular elements is used. Appropriate devices for such separation are available commercially and are well-known to the skilled artisan. They include, for example, the Exorim System, the Fresenius Hemocare Apheresis system, or the Gambro Prisma System. Plasma purified through said separation devices is then run over an array of filtration devices, said filtration possessing a higher affinity towards CD4I+ and / or CD61+ PEVs or PMP or fragments thereof in comparison to other molecules. Said filtration includes, in some embodiments, CD41+ and / or CD61+ PEVs or PMP or fragments thereof binding agents immobilized to a substrate.

[0094] In other embodiments, the agent capable of, or configured for, binding the CD41+ and / or CD61+ PEVs or PMP or fragments thereof is immobilized to a filter membrane or capillary dialysis tubing, where the plasma passes adjacent to, or through, the membranes to which said agent capable of binding the CD41+ and / or CD61+ PEVs or PMP or fragments thereof is bound. Suitable filters include those mentioned previously with respect to separation of blood components. These may be the same filters, having immobilized agents capable of binding CD41+ and / or CD61+ PEVs or PMP or fragments thereof, or may be arranged in sequence, so that the first filter divides the blood components and the secondary, tertiary, and additional filters remove one or more of the components of said CD41+ and / or CD61+ PEVs or PMP or fragments thereof.

[0095] Conjugation of the agent capable of binding the CD41+ and / or CD61+ PEVs or PMP or fragments thereof to said substrate may be accomplished by numerous means known in the art. Said means include avidin-streptavidin, cyanogen bromide coupling, or the use of a linker, such as a polyethylene glycol linker. A means of returning the blood, together with plasma substantially cleared of CD41+ and / or CD61+ PEVs or PMP or fragments thereof, back to said subject is also provided herein. Preferred approaches are chosen by one of skill in the art based on the desired application, extent of CD41+ and / or CD61+ PEVs or PMP or fragments thereof whose removal is desired, patient condition, extracorporeal method chosen, and CD41+ and / or CD61+ PEVs or PMP or fragments thereof-binding agent chosen.

[0096] In some embodiments, the methods described herein are carried out by using an affinity cartridge using the device illustrated in FIG. 1. In this device, the sample from the subj ect is passed through the lumen of a hollow fiber ultrafiltration membrane that is in intimatecontact, on the non-blood wetted side of the membrane, with immobilized lectins, which accept and immobilize CD41 + and / or CD6I + PEVs or PM P or fragments thereof. Thus, the device retains intact glycoproteins (which may be a part of a larger structure) bound by lectin, while allowing other components to pass through the lumen,

[0097] An exemplary device, described in detail in FIGS. 1-3, includes multiple channels of hollow fiber ultrafiltration membrane that form a filtration chamber. An inlet port and an effluent port are in communication with the filtration chamber. The ultrafiltration membrane is preferably an anisotropic membrane with the tight or retention side facing the bloodstream. The membrane is conveniently formed of any number of polymers known to the art, for example, polysulfone, polyethersulfone, polyamides, polyimides, cellulose acetate, or polyacrylamide. Preferably, the membrane has pores 200-700 nm in diameter, which will allow passage of subcellular nanoparticles but not platelets or most blood cells (red blood cells, 2,000 nm diameter; lymphocytes, 7,000-12,000 nm diameter; macrophages, 10,000-18,000 nm diameter). A diagram of an exemplary device is shown in FIG. 1. The device comprises a cartridge 10 comprising a blood-processing chamber 12 formed of suitable material such as polycarbonate 14. Around chamber 12 is an optional exterior chamber 16. A temperature controlling fluid can be circulated into chamber 16 through port 18 and out of port 20. The device includes an inlet port 32 for the blood and an outlet port 34 for the effluent. The device also provides one or more ports 48 and 50, for accessing the extra-channel space in the cartridge. As shown in FIGS. 1 and 2, chamber 12 contains a plurality of ultrafiltration membranes 22. These membranes preferably have a 0.3 mm inside diameter and 0.5 mm outside diameter. FIG. 3 is a cross-sectional representation of a channel 22 and shows the anisotropic nature of the membrane. As shown in FIG. 3, a hollow fiber membrane structure 40 is composed of a single polymeric material which is formed into a tubular section comprising a relatively tight ultrafiltration membrane 42 and a relatively porous exterior portion 44 in which may be immobilized lectins 46. During the operation of the device, a solution containing the lectins is loaded onto the device through port 48. The lectins are allowed to immobilize to the exterior 22 of the membrane in FIG. 2. Unbound lectins can be collected from port 50 by washing with saline or other solutions. The cartridge housing is made of polycarbonate and the fibers are held in place with polyurethane potting material. The lectins are found in the extra-lumen (or extra-capillary or extra-channel) covalently bound to a solid material 10-200 microns (or wider) in diameter. The substrate material is made of a porous silicon dioxide material(SiO₂), preferably diatomaceous earth. Approximately 35-45 grams of lectin-bound substrate is loaded into the extra-lumen space around the fibers through the polycarbonate side ports of the cartridge. During operation, blood runs along the length of the fibers and the plasma exits the pores and comes into contact with the lectin that is bound to the solid substrate.

[0098] For binding of lectins to the ultrafiltration membrane, the polymers of the ultrafiltration membrane are first activated (e.g., made susceptible for combining chemically with proteins) by using processes known in the art. Any number of different polymers and copolymers can be used. To obtain a reactive polyacrylic acid polymer, for example, carbodiimides can be used (Valuev et al., 1998, Biomaterials, 19:41-3). Once the polymer has been activated, the lectins can be attached directly or via a linker to form in either case an affinity matrix. Suitable linkers include, but are not limited to, avidin, strepavidin, biotin, protein A, or protein G. The lectins may also be directly bound to the polymer of the ultrafiltration membrane using coupling agents such as bifunctional reagents, or may be indirectly bound. In some embodiments, GNA covalently coupled to agarose can be used to form an affinity matrix.

[0099] Accordingly, in some of the methods described herein, a lectin affinity device is used and said device comprises a filtration chamber configured to receive a sample from the subject; a lectin, optionally coupled to agarose, diatomaceous earth, or aminocelite, disposed within said filtration chamber; and a porous hollow fiber membrane, wherein said membrane has pores of 200-700 nm in diameter; wherein the lectin is selected from the group consisting of: Galanthus nivalis agglutinin (GNA), Narcissus pseudonarcissus agglutinin (NPA), cyanovirin, and Concanavalin A, and mixtures thereof, wherein the cartridge is configured to remove CD41+ and / or CD61+ PEVs or PMP or fragments thereof from a sample (e.g., blood, plasma).

[0100] Processes that can be used to isolate lectins such as GNA are generally known in the art. For example, Van Damme et al. demonstrate isolating the lectin from Galanthus nivalis (snowdrop) bulbs by affinity purification with mannose or other sugars (Van Damme et al. FEBS Letters (1987) 215(1): 140-144). Use of purified GNA for affinity purification purposes has been previously demonstrated, such as for isolating glycoproteins like immunoglobulins (Shibuya et al. Archives Biochem. Biophys. (1988) 267(2):676-680). Each of the references above is hereby expressly incorporated by reference in its entirety.

[0101] Aspects of the present invention also provide a device with a filtrationchamber further comprising an inlet port and an outlet port; wherein a channel of said hollow fiber membrane is in fluidic communication with said inlet and said outlet ports; said cartridge having an extra-channel space within said chamber which surrounds said hollow fiber membrane; and wherein said lectin is, optionally, covalently coupled to agarose, diatomaceous earth, or aminocelite that is disposed within said extra-channel space proximate to an exterior surface of said membrane.

[0102] For some methods described herein, the sample (e.g., blood, or plasma) from a subject having CD41+ and / or CD61+ PEVs or PMP or fragments thereof is withdrawn from the subject and contacted with the device mentioned herein. In some embodiments, the blood is first separated into its plasma and cellular components. The blood or plasma is then contacted with the lectins to remove the CD41+ and / or CD61+PEVs or PMP or fragments thereof by binding between glycoproteins and lectins. In some embodiments, the PEVs removed comprise both CD41+ and CD61+. The plasma can then be recombined with the cellular components and returned to the subject. Alternatively, the cellular components may be returned to the subject separately. In some embodiments, the time required to remove 50% of CD41+ and / or CD61+ PEVs or PMP or fragments thereof is 5 minutes, 10 minutes, 15 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours, or any amount of time within a range defined by any two of the aforementioned times. In some embodiments, the percentage of CD41+ and / or CD61+ PEVs or PMP or fragments thereof removed in 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 hours or any amount of time within a range defined by any two of the aforementioned times is 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% or any percentage within a range defined by any two of the aforementioned values. The therapy can be repeated periodically until a desired response has been achieved. In some embodiments, the therapy can be carried out for 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours within a 24 hour period, or any amount of time within a range defined by any two of the aforementioned times. In some embodiments, the therapy can be repeated every day for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 days.

[0103] In one embodiment, the frequency and length of extracorporeal therapy is performed based on the amount of time (or blood volume) needed for reduction of CD41+ and / or CD61+ PEVs or PMP concentration to a level significant to correlate with reduction byapproximately 20% in comparison to pre-extracorporeal treatment values is judged as sufficient. In another embodiment, the reduction of CD41+ and / or CD61 + PEVs or PMP concentration to a level significant to correlate with a reduction of approximately 50% in comparison to pre-extracorporeal treatment values is determined as being sufficient. In another embodiment, the reduction of CD41+ and / or CD61+ PEVs or PMP concentration to a level significant to correlate with reduction by approximately 90% in comparison to pre-extracorporeal treatment values is determined to be sufficient.

[0104] In general, fluid is first removed from a subject (e.g., a mammal, a domestic animal, a rodent, a horse, a dog, cat, or human) and then it is processed to capture a population comprising CD41+ and / or CD6I+ PEVs or PMP or fragments thereof. The volume of fluid removed will vary' from patient to patient and will depend on a number of factors including but not limited to: age, body habits, coagulation profile, hemodynamic stability, severity of insufficiency or injury, co-morbidities, and physician preference. The amount of fluid collected can depend on a number of variables including, but not limited to, the body mass index of the donor, the availability of accessible fluid and / or tissue harvest sites, concomitant and pre-existing medications and conditions (such as anticoagulant therapy), and the clinical purpose for which the fluid is being collected.

[0105] The fluid can be obtained by any method known to a person of ordinary skill in the art. If the fluid or some fraction thereof is intended for reintroduction into a subject, the fluid should be collected in a manner that minimizes the likelihood of contamination of the fluid with potentially infectious organisms, such as bacteria and / or viruses. Thus, the fluid extraction should be performed in a sterile or aseptic manner to minimize contamination.

[0106] The fluid that is removed from a patient is then collected into a device for further processing so as to capture CD41+ and / or CD61+ PEVs or PMP. In certain embodiments, the processing of fluid is performed in a system that is configured to maintain a closed, sterile fluid pathway. This can be achieved by use of a linked set of closed, sterile containers and tubing allowing for transfer of fluid elements within a closed pathway. This processing set can be linked to a series of processing reagents (e.g., saline, or glucose, etc.) inserted into a device, which can control the addition of reagents, temperature, and timing of processing, thus relieving operators of the need to manually manage the process. In a preferred embodiment, the entire procedure fromfluid extraction through processing for CD41+ and / or CD61+ PEVs or PMP or fragments thereof capture is performed in the same facility and within the same room of the patient undergoing the procedure.

[0107] For many applications, capture of CD41+ and / or CD61+ PEVs or PMP, but not PEVs from the fluid, is desired. In certain embodiments, the entire PEV component is separated from the captured CD41+ and / or CD61+ PEVs or PMP component of the fluid. In other embodiments, only a portion or portions of the PEVs component is separated from the captured CD41+ and / or CD6I+ PEVs or PMP.

[0108] In some embodiments, the system can be automated. In another embodiment, the system has both automated and manual components. The system can include one or more disposable components connected to or mounted on a reusable hardware component or module. The automated systems of the invention can provide screen displays that prompt proper operation of the system. The automated systems can also provide a screen that provides status of the procedure and / or the step-by-step instructions as to the proper setup of the disposable components of the system. The screen can also be configured to indicate problems or failures in the system if they occur and provide "troubleshooting" guidance if appropriate. In one embodiment, the screen can be a user interface screen that allows the user to input parameters into the system through, e.g., a touch screen.

[0109] In some embodiments, the partial and fully automated systems can include a processing device (e.g., microprocessor or personal computer) and associated software programs that provide the control logic for the system to operate and to automate one or more steps of the process based on user input. In certain embodiments, one or more aspects of the system may be user-programmable via software residing in the processing device. The processing device may have one or more pre-programmed software programs in Read Only Memory (ROM). For example, in some embodiments, the processing device can have pre-programmed software tailored for processing blood, another program for processing other fluids and / or tissues. In some embodiments, the processing device can also have pre-programmed software that provides the user with appropriate parameters to optimize the process based on the user's input of relevant information, such as the type of tissue being processed, the type of post-processing manipulation required, the type of therapeutic application, etc.

[0110] In some embodiments, the system provides software that can allow for the automation of steps such as controlling the ingress and egress of fluids and tissues along particular tubing paths by controlling pumps and valves of the system; controlling the proper sequence and / or direction of activation; detecting blockages with pressure sensors; mixing mechanisms; measuring the amount of tissue and / or fluid to be moved along a particular pathway using volumetric mechanisms; maintaining temperatures of the various components using heat control devices; and integrating the separation and concentration process with timing and software mechanisms.

[0111] In some embodiments, the automated system can also include probes or sensors. In some embodiments, the system can include a probe or sensor, e.g., an optical sensor, which may be capable of detecting a change in the light refraction of the effluent that is flowing in the conduits.

[0112] In some embodiments, the sampling probe described above may be used with a testing chamber. In some embodiments, the testing chamber comprises a FACS machine. In other embodiments, the testing chamber can include any one of the following components: (1) a stage for holding a microscope slide, and (2) an automated cover slipping unit. The sampling probe can be positioned in such a way as to obtain a sample from the processing unit and then to deliver the sample into a component of the testing chamber. The operation of such a testing chamber would proceed as follows: (1) the operator has pre-placed a microscope slide onto the stage, (2) a sample of the cell suspension is obtained by the sampling probe, (3) the probe then moves in an automated fashion above the microscope slide, (4) the stage is then automatically set to move slowly in a lateral plane while (5) the sampling probe dispenses a thin layer of the cell suspension across the microscope slide, and (6) the automated cover slipping unit places a cover slip atop the slide after the sample has been dispensed onto the slide. The slide is then held in place until the operator removes it from the testing chamber, stains it with Oil Red O, and stains it for antibody based or non-antibody based stain, and quantifies the cells microscopically.

[0113] A sampling probe in line with the fluid path may also be used with a testing chamber to test for markers of interest. Such a sampling probe would consist of the following major components: (1) a spectrophotometer or fluorimeter that houses a unit that holds tube(s) or well(s) for placement of the cell sample and a colorogenic or fluorogenic protease substrate, and is connected to a digital display on the outside of the entire device that converts the chromogenicor fluorometric signal. The operation of such a sampling probe can proceed as follows: (1) the probe samples the fluid and (2) dispenses it into a chamber, (3) the operator injects an appropriate amount of the chromogenic or fluorogenic protease substrate into the port, such that the solution is dispensed into the spectrophotometer or fluorimeter tube(s) or well(s), (4) the tube(s) or well(s) and its contents incubate for an appropriate, designated period of time under controlled temperature, (5) the spectrophotometer or fluorimeter reads the contents of the tube(s) or well(s), and (6) the activity in the sample can be displayed digitally on the device.

[0114] In some embodiments, the processing device can include standard parallel or serial ports or other means of communicating with other computers or networks. Accordingly, the processing device can be a stand-alone unit or can be associated with one or more additional devices for the further processing methods described herein.

[0115] In some embodiments, the software can allow for automated collection of "run data" including, for example, the lot numbers of disposable components, temperature and volume measurements, ti ssue volume and cell number parameters, operator identity, date and time, patient identity, etc. In some embodiments, the device or system can include a character recognition system, such as a bar code reading system, which would be integrated to permit data entry of these variables (for example, disposable set lot number and expiration date, patient / sample identifiers, etc.) into the processing device as part of documentation of processing. This could reduce the opportunity for data entry errors. Such a bar code reading system can be incorporated into the processing device using a USB or other interface port and system known to the art, including Bluetooth. In this way, the device would provide integrated control of the data entry and documentation of the process. A print-out report of these parameters could then be part of the user- defined parameters of a programmed operation of the system. In some embodiments, the system is configured to integrate a printer component (hardware and driver) or printer driver in software plus an interface output connector for a printer (e.g., a USB port) in the hardware of the device.

[0116] In some embodiments, the system can be a fully automated system. For example, the user can initially select the amount of fluid to be processed, attach the system to the patient, and the system may automatically aspirate the required fluid and capture CD41+ and / or CD61+ PE Vs or PMP in an uninterrupted sequence without further user input. In some embodiments, the system can be configured to run in semi-automatic mode, during which thesystem goes through certain steps without user intervention but requires user intervention before certain processes can occur. In other embodiments, the system can be a single integrated system that displays instructions to guide the user to perform predetermined operations at predetermined times. For example, the processing device can be configured to prompt users through the steps necessary for proper insertion of tubing, chambers, and other components of the system. Accordingly, the user can ensure that the proper sequence of operations is being performed. In some embodiments, the system is configured to require confirmation of each operational step by the user to prevent inadvertent activation or termination of steps in the process. In a further embodiment, the system may initiate automated testing to confirm correct insertion of tubing, chambers, absence of blockages, etc. In yet another embodiment, the system of the present invention can be configured to be programmed to perform multiple separation and concentration processes through automated control of tissue flow through the system. This feature may be useful, for example, during surgery on a patient where fluid that would otherwise be lost is collected into the system, the CD41+ and / or CD61+ PE Vs or PMP are captured from the fluid, and the fluid is returned to the patient.

[0117] As set forth above, in some embodiments, components of the system can be disposable (referred to herein as "disposable set(s)"), such that portions of the system can be disposed of after a single use. Systems with disposable components can be useful to ensure that any surface that comes into contact with the patient's tissue will be disposed of properly after being used. In a preferred embodiment, the disposable components of the system can be pre-sterilized and packaged so as to be usable "off the shelf', that are easy to use and easy to load, and that eliminate the need for many tubing connections and complex routing of tubing connections. In another preferred embodiment, the various chambers and containers of the disposable set can include the necessary’ interfaces that are capable of communicating with the processing device of the system, such that the pumps, valves, sensors, and other devices that automate the system are appropriately activated or deactivated as needed without user intervention. The interfaces also reduce the time and expertise required to set up the system and also reduce errors by indicating how to properly set up the system and alerting the user in the event of an erroneous setup.

[0118] In some embodiments, the disposable sets may include one or more needles or syringes suitable for obtaining fluids or tissue from the patient and returning them to the patient.The type, number, and variety of the needles and syringes included will depend on the type and amount of tissue being processed. The disposable sets may further include one or more rigid or flexible containers to hold washing fluids and other processing reagents used in the system. In some embodiments, the system components, equipment, or supplies described herein can be provided in the form of a kit.

[0119] In some embodiments, the system includes a re-usable component. The re¬ usable component of the system can comprise, consist essentially of, a user interface screen and USB ports, an interlocking or docking device or configuration to connect the disposable set such that the disposable set is securely attached to and interfaces with the re-usable hardware component and other associated devices. In some embodiments, the re-usable component can also house a processing device as described herein, which contains pre-programmed software for carrying out several different tissue processing procedures and selectively activating the various pumps and valves of the system accordingly. The processor can also include data storage capability for storing donor / patient information, processing or collection information, and other data for later downloading or compilation. The re-usable component can be used with a variety of disposable sets. Disposable and re-usable components can be connected through, e.g., an interlocking device or configuration such that the disposable set is securely attached to and interfaces with the re¬ usable hardware component in a manner that the processing device present on the re-usable component can control, i.e., send and receive signals to and from the various components of the disposable set as well as various components of the re-usable component and other associated devices and systems. In some embodiments, the system can be configured such that it can detect an improperly loaded disposable component. For example, in some embodiments, the components of each disposable set can have color-guided marks to properly align and insert the tubing, chambers, etc. into appropriate places in the system. In additional embodiments, the system disclosed herein can be a portable unit. For example, the portable unit can be configured to be moved from one location to another. In certain other embodiments, the portable unit is suitable for a patient's bedside. In some embodiments, the portable unit can be part of a system which can be moved from patient to patient. Accordingly, the portable unit can be on wheels which lock in place and, thus, can be easily placed and used in a convenient location in a stable and secure position throughout the procedure. In other embodiments, the portable unit can be designed for set-up and operation on a flat surface such as a table top. The portable unit can also be enclosed in a housingunit. The portable unit can also include hangers, hooks, labels, scales, and other devices to assist in the procedure. Each of the re-usable components of the system described herein, such as the centrifuge, processing device, display screen, can be mounted on the portable unit of the system.

[0120] In some embodiments, the system is configured such that the user can connect the disposable set to the re-usable component, input certain parameters using the user interface, attach the system to the patient, and the system automatically performs all of the steps needed in an uninterrupted sequence using pre-programmed and / or user input parameters.Preparation of the Device for Hemopurification

[0121] The extracorporeal circuit is to be connected;

[0122] The extracorporeal circuit is primed and rinsed with a minimum of two liters of priming solution;

[0123] An anticoagul nt, such as heparin, will be added per liter of priming solution if needed to prevent clotting of the blood circuit;

[0124] The initial flow rate for priming will be 200-250 mL / min and up to 400-500 mL / min for several minutes, while using a priming solution, not blood, to increase the shear forces inside the fibers to encourage the dislodgement of microbubbles. During this procedure, all bubbles are removed from the tubing and the cartridge by gentle tapping.Therapy

[0125] For use on a subject with established vascular access, the subject will be connected to the dialysis machine, which pumps blood from the subject through the cartridge and returns the purified blood to the subject. Blood flow rates are typically maintained at up to 200 mL / min. In some embodiments, the flow rate of the blood or organ perfusate is 18 mL / min. In some embodiments, the flow rate of the blood or organ perfusate is 19 mL / min. Heparin injections are most often used to prevent blood clotting when the procedure is performed on a human. Typical treatment times are up to 4 hours. Longer times may be used to increase the effectiveness of the treatment. At the end of the treatment, the blood in the tubing and cartridge is washed back into the subject in the case of a treatment done on a human. The machine is then disconnected from thesubject or the organ, and the contaminated cartridge and blood tubing are properly disposed.

[0126] During the therapy on a person with the device, testing will be performed to measure the activated clotting times (ACT) for monitoring anticoagulation.Results

[0127] Pre- and post-treatment samples from a subject that will receive the therapy above will have a significantly reduced CD41+ PEVs or PMP or fragments thereof in the blood post-therapy.

[0128] Samples collected from the subject at various intervals after therapy with a lectin affinity hemofiltration device will show reduced levels of CD41+ PEVs or PMP, or fragments thereof after treatment with the device vs. pre-treatment.EXAMPLESExample 1 — Removal of Platelet-Derived Extracellular Vesicles (PEVs), or fragments thereof in a subject

[0129] This example pertains to methods of removing PEVs or fragments thereof from a subject in need. The methods of removing PEVs or fragments thereof from a subject in need were performed using the methods discussed below. In Example 1, the plasma used was healthy normal plasma.Hemopurifier® Treatment of Pooled Human Plasma

[0130] De-identified, apheresis-derived pooled normal human plasma was obtained from a supplier using K2EDTA as the anticoagulant. The plasma tested negative for a panel of viral markers. According to the supplier, all plasma was collected in compliance with FDA regulations. Samples were fully de-identified prior to purchase, and no identifiable donor information was made available to the researchers. A total of 300 mb of pooled human pl sma was centrifuged at 1,000 * g for 5 minutes to remove large cellular debris. Following clarification, 250 m of the supernatant was transferred to a reservoir for HP treatment circulation, then 50 mL of plasma was collected and stored to serve as the pre-treatment (baseline) control. Prior toinitiating treatment of the remaining 200 mL of plasma, the HP circuit was flushed with 1 L of sterile 0.9% saline to ensure proper equilibration. The 200 mL of plasma was then circulated through the Hemopurifier® at a flow rate of 100 mL / min, and plasma samples were collected after 9.6, 14.4, and 19.6 total volume passes. This sample schedule corresponded to HP clinical treatment durations equivalent to 4-, 6-, and 8-hour treatment, when considering that an average adult human has a 5L blood volume and the HP clinical procedure can be performed using an extracorporeal flow rate of 200 mL / min. In this experiment, baseline and HP-treated plasma samples were stored frozen in 1 mL aliquots at -80°C.Extracellular Vesicle Isolation

[0131] Microparticles (extracellular vesicles with a size of 100-500 nm) were isolated from 1 mL of baseline and timepoint plasma samples by first performing two pre-clearing centrifugation steps of 2,500 x g for 15 minutes at room temperature, recovering 850 pL of supernatant and further centrifugating at 18,000 x g for 45 minutes at 4°C to pellet the EV s. Plasma supernatant was completely removed, and large EV pellets were resuspended in 100 pL of 0.22 pm PES membrane-filtered PBS, incubated for 45 minutes at room temperature to allow for complete resuspension, then separated into 25 pL aliquots and stored at -80°C prior to analysis.Nanoparticle Flow Cytometry Analysis

[0132] Extracellular vesicles were quantified using the single-particle detection flow cytometer. The total EVs were measured using the phospholipid bilayer dye MemGlow488nm (MemGlow™ 488: Fluorogenic Membrane Probe, Cytoskeleton). The concentration and size distribution profile of the EVs was determined. The identification of platelet microvesicles was determined through the staining, and a one-hour incubation at room temperature, of 100 nM MemGlow488nm and APC anti-CD41 (BioLegend Inc., San Diego, CA, USA).

[0133] As illustrated in FIG. 5 A, the total number of 100-500 nm microparticles measured at baseline was just over 4 108 / mL of plasma with over 96% of these microparticles removed after a 4-hour Hemopurifier® treatment with not much further depletion at subsequent time intervals. This indicates that the Hemopurifier® is highly effective in depleting microparticles in this size range and the 4-hour treatment appears sufficient for maximum removal. The totalnumber of CD41+ve microparticles at baseline was 1.93 107 / mL of plasma with over 98.5% of these microparticles removed after a 4-hour treatment with the Hemopurifier® and subsequently undetectable at later time points as illustrated in FIG. 5B. In another analysis, the total number of CD41+ve microparticles at baseline was 1.31 107 / mL of plasma, which was removed after a 4-hour treatment with the Hemopurifier® as illustrated in FIG. 4.Example 2 — Removal of Extracellular Vesicles (PEVs), or fragments thereof in a subject with Rheumatoid Arthritis

[0134] This example pertains to methods of removal of PEVs or fragments thereof from a subject having rheumatoid arthritis. The methods of removing PEVs or fragments thereof from a subject having rheumatoid arthritis were performed using the methods discussed below. In Example 2, the plasma used was rheumatoid arthritis plasma.Rheumatoid Arthritis Plasma Treatment

[0135] A 250 mL bulk volume of plasma (Phase Clinical Services, BPS-RF-07) from an individual with rheumatoid arthritis (RF = 79.3 lU / 'mL) was treated by the Aethlon Hemopurifier (AEMD23004-123) by circulating at a flow rate of 12-24 mL / min using a peristaltic pump, and plasma samples were collected at various timepoints. Extracellular vesicles (EVs) were enriched from 1 mL plasma samples by centrifugation at 18,000 x g for 45 minutes at 4 °C, followed by resuspension of the pelleted EVs in 100 pL of 0.22 pm PES membrane-filtered PBS.Nanoparticle Flow Cytometry Analysis

[0136] EVs were quantified using the single-particle detection NanoFCM™ Flow Analyzer U30 instrument (NanoFCM, Inc., Xiamen, China). To assess changes in the concentration of platelet derived EVs, CD41+ EVs were quantified after a one-hour room temperature incubation with 166.7 pM of APC anti-CD41 (BioLegend Inc., San Diego, CA, USA, Cat. #303710) in combination with 5 nM of a MemGlow phospholipid bilayer dye (MemGlow™ 488: Fluorogenic Membrane Probe, Cytoskeleton). The concentration and size distribution profile of the EVs was determined utilizing the manufacturer’s provided calibration kits (NanoFCM™ Silica Nanospheres Cocktail #3; Cat. #S17M-MV; NanoFCM™ Quality Control Nanospheres; Cat. #QS2503).RNA Isolation and Analysis

[0137] Total miRNA was isolated from the 18,000 x g cleared RA plasma using the miRNeasy Serum / Plasma Advanced isolation kit (Qiagen, Cat. #217204) and collected in 25 pL of RNAse free water. Reverse transcription (RT) of miRNA was carried out according to the miRCURY LNA miRNA SYBR® Green PCR Biofluid Samples Handbook (Qiagen, Cat. #339340) in a total reaction volume of 20 pL. The amount of RNA template loaded was 3 pL. The cDN A was diluted 1:15 in nuclease-free water and 3 L was used to prepare each miRCURY LNA PCR reaction (Qiagen, Cat. #339306) to measure specific miRNAs associated with platelet activity. The miRNA levels (miR-126-3p, miR-21-5p, and miR-142-3p) were normalized against synthetic spike-in controls (cel-39 and UniSP6) to enable relative comparison between samples by applying the 2-AACt method.Results

[0138] FIG. 6A illustrates a nanoparticle flow cytometry analysis of EVs isolated from pooled human plasma HP treatment timepoint samples. The samples demonstrate a concentration reduction of CD41+ EVs ranging anywhere from 40-1200 nm in diameter, stained with APC anti-CD41 and MemGlow™ 488. The data shown represents the average of two technical replicates and their respective standard deviation.

[0139] As shown in FIG. 6A, the total number of CD41+ EVs was observed to be 1.19 *108 / mL in the initial plasma with a time dependent reduction occurring as it circulates through the Hemopurifier. At the 4-hour treatment interval which is comparable to Aethlon’s clinical treatment protocol, more than 98.5% of the CD41+ EVs have been removed.

[0140] FIG. 6B illustrates RT-qPCR data collected from RA plasma samples collected during the Hemopurifier treatment. The data shown represents the average of two technical replicates and their respective standard deviation.?\s shown, three platelet-associated miRNAs were reduced: miR-126-3p, miR-21-5p, and miR-142-3p, known to promote thrombosis, endothelial dysfunction, and vascular inflammation. After 4 hours of HP treatment, circulating levels of these miRNAs dropped to 40%, 65%, and 32% of baseline, respectively (FIG. 6B).Example 3 - Removal of Platelet-Derived CD61+ Extracellular Vesicles (EVs), or fragments thereof in a subjectHuman Plasma Treatment

[0141] Three biologically distinct 250 mL volumes of pooled apheresis-derived K2EDTA healthy human plasma (Innovative Research, IPLAK2E1000ML: Lot#43986, Lot#59506, Lot#59735) were circulated through Aethlon Hemopurifiers (HPs) at a flow rate of <100 mL / min, and plasma samples were collected at clinically relevant timepoints. Extracellular vesicles (EVs) were enriched from 1 mL plasma samples by centrifugation at 18,000 x g for 45 minutes at 4 °C, followed by resuspension of the pelleted EVs in 100 pL of 0.22 pm PES membrane-filtered PBS.Nanoparticle Flow Cytometry Analysis

[0142] EVs were quantified using the single-particle detection NanoFCMTM Flow Analyzer LOO instrument (NanoFCM, Inc., Xiamen, China). To assess changes in the concentration of platelet derived EVs, CD61+ EVs were quantified after a one-hour room temperature incubation with 166.7 pM of APC anti-CD61 (BioLegend Inc., San Diego, CA, USA, Cat. #336411) in combination with 5 nM of a MemGlow phospholipid bilayer dye (MemGlow™ 488: Fluorogenic Membrane Probe, Cytoskeleton). The concentration and size distribution profile of the EVs was determined utilizing the manufacturer’s provided calibration kits (NanoFCM ™ Silica Nanospheres Cocktail #3; Cat. #S17M-MV; NanoFCM™ Quality Control Nanospheres; Cat. #QS2503).Results

[0143] FIG. 7 shows the total number of CD61+ EVs (100-500 nm) to range from 0.54 - 1.1 107 / mL of plasma prior to the Hemopurifier treatment. At the 4-hour treatment timepoint, which is representative of Aethlon’ s clinical treatment protocol, a reduction of >99% of CD61+ EVs was observed across the three samples. The data shown for each timepoint represents the average of two technical replicates and their respective standard deviations. The lowest limit of detection in this assay was 1.3 104 / mL.TERMINOLOGY

[0144] In at least some of the previously described embodiments, one or more elements used in an embodiment can interchangeably be used in another embodiment unless such a replacement is not technically feasible. It will be appreciated by those skilled in the art that various other omissions, additions, and modifications may be made to the methods and structures described above without departing from the scope of the claimed subject matter. All such modifications and changes are intended to fall within the scope of the subject matter, as defined by the appended claims.

[0145] With respect to the use of substantially any plural and / or singular terms herein, those having skill in the art can translate from the plural to the singular and / or from the singular to the plural as is appropriate to the context and / or application. The various singular / plural permutations may be expressly set forth herein for sake of clarity.

[0146] It will be understood by those within the art that, in general, terms used herein, and especially in the appended claims (e.g., bodies of the appended claims) are generally intended as “open” terms (e.g., the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” etc.). It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases “at least one” and “one or more” to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles “a” or “an” limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases “one or more” or “at least one” and indefinite articles such as “a” or “an” (e.g., “a” and / or “an” should be interpreted to mean “at least one” or “one or more”); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should be interpreted to mean at least the recited number (e.g., the bare recitation of “two recitations,” without other modifiers, means at least two recitations, or twoor more recitations). Furthermore, in those instances where a convention analogous to “at least one of A, B, and C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). In those instances where a convention analogous to “at least one of A, B, or C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, or C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). It will be further understood by those within the art that virtually any disjunctive word and / or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or “B” or “A and B.”

[0147] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.

[0148] As will be understood by one of skill in the art, for any and all purposes, such as in terms of providing a written description, all ranges disclosed herein also encompass any and all possible sub-ranges and combinations of sub-ranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third, and upper third, etc. As will also be understood by one skilled in the art, all language such as “up to,” “at least,” “greater than,” “less than,” and the like includes the number recited and refers to ranges which can be subsequently broken down into sub-ranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member. Thus, for example, a group having 1-3 articles refers to groups having 1, 2, or 3 articles. Similarly, a group having 1-5 articles refers to groups having 1, 2, 3, 4, or 5 articles, and so forth.

[0149] The terms “about” or “around” as used herein refer to a quantity, level,value, number, frequency, percentage, dimension, size, amount, weight, or length that varies by as much as 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length.

[0150] Throughout this specification, unless the context requires otherwise, the words “comprise,” “comprises,” and “comprising” will be understood to imply the inclusion of a stated step or element or group of steps or elements but not the exclusion of any other step or element or group of steps or elements.

[0151] By “consisting of’ is meant including, and limited to, whatever follows the phrase “consisting of.” Thus, the phrase “consisting of’ indicates that the listed elements are required or mandatory, and that no other elements may be present. By “consisting essentially of’ is meant including any elements listed after the phrase and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase “consisting essentially of’ indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present depending upon whether or not they materially affect the activity or action of the listed elements.

[0152] While various aspects and embodiments have been disclosed herein, other aspects and embodiments will be apparent to those of skill in the art. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting, with the true scope and spirit being indicated by the following claims.

Claims

WHAT IS CLAIMED IS:

1. A lectin, comprised in an extracorporeal device, suitable for use in a method of reduci ng an amount of CD41+ and / or CD61+ Platelet Derived Extracellular Vesicles (PEVs) in a subject in need thereof or a sample from a subject, the method comprising:a) contacting a sample from said subject, which contains CD41+ and / or CD6I+ Platelet Derived Extracellular Vesicles (PEVs), optionally, wherein the CD41+ and / or CD61+ are on the same PEVs, such as blood or plasma, with a support comprising a lectin, such as a membrane or bead, preferably comprised in an extracorporeal device, for a time sufficient to allow the CD41+ and / or CD61 + PEVs to bind to said support; andb) optionally, reintroducing the sample obtained after (a) into said subject, wherein the sample obtained after (a) has a reduced amount of the CD4I + and / or CD61+ PEVs, as compared to the sample of said subject prior to (a);c) optionally measuring the amount of CD41+ and / or CD61+ PEV s in the sample from said subject prior to (a), after (a), during (b) or after (b) or any combination thereof or measuring or analyzing the amount of CD41+ and / or CD61+ PEVs present on the support after (a); ord) optionally selecting or identifying the subject as one in need of removal of CD41+ and / or CD61+ PEVs.

2. The lectin of claim 1, wherein the subject has Multiple Sclerosis (MS), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, a hemorrhagic disorder such as disseminated intravascular coagulation (DIC), thrombosis, or any combination thereof.

3. The lectin of claim 2, wherein the cardiovascular disease comprises hypertension, heart failure, Acute Coronary Syndrome (ACS), or Acute Myocardial Infarction (AMI).

4. The lectin of claim 2, wherein the thrombosis comprises deep vein thrombosis, pulmonary embolism, stroke, or Myocardial infarction (MI).

5. The lectin of any one of claims 1-4, wherein the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than 1 * 10sPEVs per mL and / or after (a) is less than 1×108PEVs per mL.

6. The lectin of any one of claims 1-5, wherein the contacting reduces the amount of platelet-associated miRNAs in the sample by 30% or more.

7. The lectin of any one of claims 1-6, wherein the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than 80 events / pl or the amount of CD41 + and / or CD61 + PEVs in the sample after (a) is less than or equal to 80 events / pl, preferably greater than or equal to a platelet / absolute lymphocyte ratio (PLR) of 160.

8. The lectin of any one of claims 1—7, wherein the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs when the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than or equal to 80 events / pl, preferably greater than or equal to a platelet / absolute lymphocyte ratio (PLR) of 160.

9. The lectin of any one of claims 1-8, wherein the lectin is suitable for use in reducing off-targeting of a CD41 -directed therapy in the subject.

10. A method for reducing an amount of CD41+ and / or CD61+ Platelet Derived Extracellular Vesicles (PEVs), in a subject in need thereof or a sample from a subject, the method comprising:a) contacting a sample from said subject, which contains CD41+ and / or CD61+ Platelet Derived Extracellular Vesicles (PEVs), optionally, wherein the CD41+ and / or CD61+ are on the same PEVs, such as blood or plasma, with a support comprising a lectin, such as a membrane or bead, preferably comprised in an extracorporeal device, for a time sufficient to allow the CD41+ and / or CD61 + PEVs to bind to said support; andb) optionally, reintroducing the sample obtained after (a) into said subject, wherein the sample obtained after (a) has a reduced amount of the CD41+ and / or CD61+ PEVs, as compared to the sample of said subject prior to (a);c) optionally measuring the amount of CD 1+ and / or CD61+ PEV s in the sample from said subject prior to (a), after (a), during (b) or after (b) or any combination thereof or measuring or analyzing the amount of CD41+ and / or CD61+ PEVs present on the support after (a); ord) optionally selecting or identifying the subject as one in need of removal of CD41+ and / or CD61+ PEVs.

11. The method of claim 10, wherein the subject has Multiple Sclerosis (MS), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, a hemorrhagic disorder such as disseminated intravascular coagulation (DIC), thrombosis, or any combination thereof.

12. The method of claim 11, wherein the cardiovascular disease comprises hypertension, heart failure, Acute Coronary Syndrome (ACS), or Acute Myocardial Infarction (AMI).

13. The method of claim 11, wherein the thrombosis comprises deep vein thrombosis, pulmonary embolism, stroke, or Myocardial infarction (MI).

14. The method of any one of claims 10—13, wherein the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than 80 events / pl or the amount of CD41+ and / or CD61+ PEVs in the sample after (a) is less than or equal to 80 events / pl, preferably greater than or equal to a platelet / absolute lymphocyte ratio (PLR) of 160.

15. The method of any one of claims 10-13, wherein the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs when the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than or equal to 80 events / pl, preferably greater than or equal to a platelet / absolute lymphocyte ratio (PLR) of 160.

16. A method for treating, inhibiting or ameliorating multiple sclerosis (MS), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis (SS), cardiovascular diseases, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, a hemorrhagic disorder such as disseminated intravascular coagulation (DIC), thrombosis in a subject in need thereof, the method comprising:(a) contacting a sample from said subject, which contains CD41+ and / or CD61+ Platelet Derived Extracellular Vesicles (PEVs), optionally, wherein the CD41+ and / or CD61+ are on the same PEVs, such as blood or plasma, with a support comprising a lectin, such as a membrane or bead, preferably comprised in an extracorporeal device, for a time sufficient to allow the CD41+ and / or CD61+ PEVs to bind to said support; and(b) reintroducing the sample obtained after (a) into said subject, wherein the sample obtained after (a) has a reduced amount of the CD41+ and / or CD61+ PEVs, as compared to the sample of said subject prior to (a);(c) optionally measuring the amount of CD41+ and / or CD61+ PEVs in the sample from said subject prior to (a), after (a), during (b), or after (b), or any combination thereof, or measuring or analyzing the amount of CD41+ and / or CD61+ PEVs present on the support after (a);(d) optionally selecting or identifying a subject in need of removal of CD41 + and / or CD61 + PEVs;(e) optionally selecting or identifying said subject for receiving a therapy for multiple sclerosis (MS), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, a hemorrhagic disorder such as disseminated intravascular coagulation (DIC), thrombosis, or a blood cell disorder; or(f) optionally administering to said subject a therapy for Multiple Sclerosis (MS), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, a hemorrhagic disorder such as disseminated intravascular coagulation (DIC), thrombosis, or a blood cell disorder, such as an antibody or binding fragment thereof (e.g., an ScFv or Fab fragment) specific for CD41 or an immune cell having a chimeric antigen receptor specific for CD41 (e.g., a T cell or NK cell).

17. The method of claim 16, wherein the therapy comprises administering a vaccine, a surgery, a drug, a monoclonal antibody, intravenous immunoglobulin (IVIG), an extracorporeal therapy, an immunotherapy, a chemotherapy, radiation, a blood transfusion, a transplantation, behavioral therapy, or any combination thereof.

18. The method of claim 17, wherein the immunotherapy comprises administering a vaccine, an immunogenic composition, an inhibitor of one or more of PD-1, CTLA-4, CCR2, or CCR5, or any combination thereof.

19. The method of claim 16, wherein the therapy comprises administering atezolizumab (TECENTRIQ®), durvalumab (IMFINZI®), avelumab (BAVENCIO®), pembrolizumab (KEYTRUDA®), nivolumab (OPDIVO®), cemiplimab (LIBTAYO®), corticosteroids, muscle relaxants, plasma exchange, immunosuppressants, Non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biological agents, physical therapy, occupational therapy, RITUXAN® (rituximab), BENLYSTA® (belimumab), Actemra® (tocilizumab), ORENCIA® (abatacept), anticoagulants, antiplatelet agents, thrombolytics, steroids, antibiotics, Aricept® (Donepezil), Exelon® (Rivastigmine), Razadyne® (Galantamine), ADUHELM® (Aducanumab), LEQEMBI® (Lecanemab), or combinations thereof.

20. The method of any one of claims 16-19, wherein the cardiovascular disease comprises hypertension, heart failure, Acute Coronary Syndrome (ACS), or Acute Myocardial Infarction (AMI).

21. The method of any one of claims 16-20, wherein the thrombosis comprises deep vein thrombosis, pulmonary embolism, stroke, and / or Myocardial infarction (MI),22. The method of any one of claims 16-21, wherein the therapy comprises an agent that targets CD41, such as an immunotherapy, CD41 -targeting nanoparticles, anti-CD41 aptamers, CD41 -targeting ligands, CD41 -targeting small molecule inhibitors, or any combination thereof.

23. The method of any one of claims 16-22, wherein the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than or equal to 80 events / pl or the amount of CD41 + and / or CD61+ PEVs in the sample after (a) is less than or equal to 80 events / pl, preferably greater than or equal to a platelet / absolute lymphocyte ratio (PLR) of 160.

24. The method of any one of claims 16-23, wherein the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs when the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than or equal to 80 events / pl, preferably greater than or equal to a platelet / absolute lymphocyte ratio (PLR) of 160.

25. The method of claim 16, wherein the method is a method for treating or ameliorating rheumatoid arthritis (RA).

26. The method of any one of claims 16-25, wherein the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than 1 * 108PEVs per mb and / or after (a) is less than 1×108PEVs per mE,27. The method of any one of claims 16-25, wherein the contacting reduces the amount of platelet-associated miRNAs in the sample by 30% or more.

28. A method for reducing off-targeting of a CD41 -directed therapy in a subject in need thereof, the method comprising:(a) contacting a sample from said subject, which contains CD41+ and / or CD61+ Platelet Derived Extracellular Vesicles (PEVs), optionally, wherein the CD41+ and / or CD61+ are on the same PEVs, such as blood or plasma, with a support comprising a lectin, such as a membrane or bead, preferably comprised in an extracorporeal device, for a time sufficient to allow the CD41+ and / or CD61+ PEVs to bind to said support; and(b) reintroducing the sample obtained after (a) into said subject, wherein the sample obtained after (a) has a reduced amount of the CD41+ and / or CD61+ PEVs, as compared to the sample of said subject prior to (a);(c) optionally measuring the amount of CD41+ and / or CD61+ PEVs in the sample from saidsubject prior to (a), after (a), during (b) or after (b) or any combination thereof or measuring or analyzing the amount of CD41+ and / or CD61+ PEVs present on the support after (a);(f) optionally selecting or identifying a subject in need of removal of CD41+ and / or CD61+ PEVs;(g) optionally selecting or identifying said subject for receiving a therapy for multiple sclerosis (MS), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, a hemorrhagic disorder such as disseminated intravascular coagulation (DIC), or thrombosis; or(h) optionally administering to said subject a therapy for Multiple Sclerosis (MS), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, a hemorrhagic disorder such as disseminated intravascular coagulation (DIC), thrombosis, such as an antibody or binding fragment thereof (e.g., an ScFv or Fab fragment) specific for CD41 or an immune cell having a chimeric antigen receptor specific for CD41 (e.g., a T cell or NK cell).

29. The method of claim 28, wherein the cardiovascular disease comprises hypertension, heart failure, Acute Coronary Syndrome (ACS) or Acute Myocardial Infarction (AMI).

30. The method of claim 28, wherein the thrombosis comprises deep vein thrombosis, pulmonary embolism, stroke and / or Myocardial infarction (MI).

31. The method of any one of claims 28-30, wherein the therapy comprises an agent that targets CD41, such as an immunotherapy, CD41 -targeting nanoparticles, anti-CD41 aptamers, CD41 -targeting ligands, CD41 -targeting small molecule inhibitors, or any combination thereof.

32. The method of any one of claims 28-31, wherein the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than or equal to 80 events / pl or the amount of CD41 + and / or CD61+ PEVs in the sample after (a) is less than or equal to 80 events / pl, preferably greater than or equal to a platelet / absolute lymphocyte ratio (PLR) of 160.

33. The method of any one of claims 28-32, wherein the subject is selected or identified as one in need of removal of CD41+ and / or CD61+ PEVs when the amount of CD41+ and / or CD61+ PEVs in the sample prior to (a) is greater than or equal to 80 events / pl, preferably greater than or equal to a platelet / absolute lymphocyte ratio (PLR) of 160.

34. The method of any one of claims 10-33, further comprising repeating steps (a) and / or (b).

35. The lectin or method of any one of the preceding claims, wherein the lectin is selected from the group consisting of Galanthus nivalis lectin (GNA), Narcissus pseudonarcissus lectin (NPA), Allium sativum lectin (ASA), Lens culinaris lectin (LCH), Sambucus nigra lectin (SN A), Maackia amurensis lectin (MAL), and concanavalin A.

36. The lectin or method of any one of the preceding claims, wherein the lectin is Galanthus nivalis agglutinin (GNA).

37. The lectin or method of any one of the preceding claims, wherein the extracorporeal device comprises a hollow fiber cartridge comprising the lectin and wherein the blood or plasma flows through hollow fibers of the hollow fiber cartridge.

38. The lectin or method of claim 37, wherein the hollow fibers of the hollow fiber cartridge comprise a pore size that excludes cellular components of the blood or plasma from contacting the lectin.

39. The lectin or method of claim 38, wherein the pore size is 200-500 nm.

40. The lectin or method of any one of the preceding claims, wherein the lectin is immobilized or adsorbed onto a solid support, and the hollow fiber cartridge comprises the lectin immobilized or adsorbed on the solid support.

41. The lectin or method of claim 40, wherein the solid support comprises diatomaceous earth.

42. The lectin or method of any one of the preceding claims, wherein the lectin is immobilized on a support that comprises a material selected from the group consisting of Sepharose, agarose, latex, glass, thermoplastic polymers, polystyrene, polyethylene beads, polyvinyl, diatomaceous earth, nitrocellulose, and silicon.

43. The lectin or method of any one of the preceding claims, wherein the sample obtained after (a) has a reduced amount of the CD41+ PEVs.

44. The lectin or method of any one of the preceding claims, wherein the sample obtained after (a) has a reduced amount of the CD61+ PEVs.

45. The lectin or method of any one of the preceding claims, wherein the sample obtained after (a) has a reduced amount of both the CD41+ PEVs and the CD61+ PEVs, optionally, wherein the CD41+ and / or CD61+ are on the same PEVs.